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It's just as if a man were wounded with an arrow thickly smeared with poison.  
His friends & companions, kinsmen & relatives would provide him with a surgeon, and the 
man would say, 'I won't have this arrow removed until I know whether the man who wounded 
me was a noble warrior, a priest, a merchant, or a worker.' He would say, 'I won't have this 
arrow removed until I know the given name & clan name of the man who wounded me... until 
I know whether he was tall, medium, or short... until I know whether he was dark, ruddy-
brown, or golden-colored... until I know his home village, town, or city... until I know 
whether the bow with which I was wounded was a long bow or a crossbow... until I know 
whether the bowstring with which I was wounded was fiber, bamboo threads, sinew, hemp, or 
bark... until I know whether the shaft with which I was wounded was wild or cultivated... until 
I know whether the feathers of the shaft with which I was wounded were those of a vulture, a 
stork, a hawk, a peacock, or another bird... until I know whether the shaft with which I was 
wounded was bound with the sinew of an ox, a water buffalo, a langur, or a monkey.' He 
would say, 'I won't have this arrow removed until I know whether the shaft with which I was 
wounded was that of a common arrow, a curved arrow, a barbed, a calf-toothed, or an 
oleander arrow.'  
The man would die and those things would still remain unknown to him. 
 
“The parable of the poisoned arrow”. From the Shorter Exhortation to Māluṅkya Cūḷa 
Māluṅkyovāda Sutta (MN 63) 
  
ABSTRACT 
Background Critical illness leads to major alterations in metabolism. The net result is a state 
where catabolism predominates over anabolism. The associated loss of lean body mass is 
significant and potentially harmful. It is commonly held that providing calories and protein 
from nutrition may attenuate this response. Despite significant research efforts, an optimal 
dose for these therapies remains to be defined.  
The metabolic rate of ICU patients is readily measured by indirect calorimetry. Questions 
regarding the accuracy of modern instruments in the setting of mechanical ventilation have 
been an impediment to wider application of this technique. The physiological effects of 
common nutritional interventions on protein balance are difficult to assess in clinical practice 
but can be quantified using stable isotope tracers.     
Aims The studies of this thesis had two main aims: to validate techniques for gas exchange 
measurements in ICU, and to describe the effects of energy and/or amino acid 
supplementation on protein kinetics. In studies I and II we evaluated the measurement 
properties of three new instruments for indirect calorimetry in mechanically ventilated ICU 
patients against a clinical gold standard (Deltatrac). Study III investigated the effects of a 
supplemental amino acid infusion on whole-body protein balance in critically ill patients. In 
study IV, we quantified whole-body protein kinetics after 24 hours of full-dose or half-dose 
enteral nutrition in a randomized cross-over study design. 
Results In study I, we performed 48 measurements with the evaluated instruments and 
reference method in sequence. Mean resting energy expenditure (REE) was similar between 
Quark RMR and Deltatrac (p = 0.17). Mean REE from CCM Express was 64% higher than 
Deltatrac (p <0.001). In study II we conducted 48 simultaneous measurements with the 
evaluated instruments and Deltatrac. Compared to Deltatrac, both Quark RMR and E-
sCOVX overestimated REE with similar bias and 95% limits of agreement. In study III, a 24-
hour intravenous amino acid infusion resulted in a positive protein balance during the study 
period (p = 0.0016) without increasing amino acid oxidation (p = 0.147). In study IV, whole-
body protein kinetics could be determined in six patients during half-dose and full-dose 
enteral nutrition. An improvement in protein balance was observed during full-dose nutrition 
(p = 0.044). 
Conclusions Measured energy expenditure is variable between instruments for indirect 
calorimetry. Apart from one device, agreement compared to the reference method was better 
than what is commonly accepted for other monitoring technologies in critical care. The 
studies of protein kinetics indicate that an increase in energy or amino acid delivery improves 
whole-body protein balance in critically ill patients. Indirect calorimetry and tracer techniques 
are promising methods to further our understanding of alterations in energy metabolism and 
substrate utilization during critical illness. In turn, this knowledge may assist in the 
development of clinical trials with patient-centered outcomes.  
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1 INTRODUCTION 
There is no universal definition of critical illness. The only common feature of patients 
admitted to an intensive care unit (ICU) is that they are considered too sick to safely reside in 
another part of the hospital, and that there is curative or palliative treatment to offer. 
Although the origins of intensive care medicine are often traced to centralization of simple 
respiratory support during the polio epidemics of the 1950s, the evolution of medical 
technology for monitoring and life support now permits patients to stay alive well beyond 
what was thought possible only a few generations ago 1. Physiological changes during critical 
illness depend on a complex interplay of patient factors and medical interventions. It is 
difficult to determine what is optimal, or even normal, under these conditions. This holds 
especially true for the metabolic alterations in ICU patients.  
Although much work has been done to develop our knowledge in this field, many issues 
remain to be explored. A central problem to monitoring metabolism in intensive care is that 
the clinical parameters of interest are often unavailable to conventional observation tools. 
This invariably results in a black box approach to patient care. The purpose of this thesis is to 
improve our understanding of alterations in energy and protein metabolism in the critically 
ill, both regarding how these changes can be monitored and the response to nutritional 
therapies. The studies included evaluate current techniques to monitor energy expenditure 
and investigations of substrate utilization in vivo. To put these research projects into context, 
the following section will briefly describe the biology of energy metabolism in humans, 
applications of indirect calorimetry in intensive care, and the major metabolic changes 
associated with critical illness. 
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2 BACKGROUND 
2.1 ENERGY METABOLISM 
2.1.1 Bioenergetics 
Energy, roughly defined, is a quantitative property transferred between objects to perform 
work or generate heat. Entropy is a measurement of the dispersion of energy within a system, 
i.e. the number of states that the system can take on. In chemistry, energy is transferred by re-
arranging bonds between atoms to more energetically favorable states, increasing entropy. 
The basis of biological life is to create and maintain a stable internal environment 
(=homeostasis) by generating mechanical energy and heat from chemical energy in 
compartmentalized reactions. Order is achieved by increasing disorder of the environment in 
exchange reactions, what Erwin Schrödinger described as “feeding on negative entropy” 2.  
The energy requirements of humans are almost exclusively met from the oxidation of 
glucose, fat and amino acids by molecular oxygen. In order to effectively utilize the energy 
liberated in these reactions, they are catalyzed in several enzymatic steps through the TCA 
cycle, extracting energy through the formation of reducing agents (NADH and FADH2) 
3. 
These generate an electrochemical gradient of protons over the mitochondrial inner 
membrane that powers the formation of ATP from ADP by a process called oxidative 
phosphorylation. ATP has several benefits as an intermediary for energy transfer: it is stable 
in an aqueous solution at physiologic pH but only requires water as a reactant in enzymatic 
hydrolysis to ADP + [PO4]
3- 4. Hydrolysis of the phosphoanhydride bond is very energetically 
favorable, with a Gibbs free energy of -50-70 kJ/mol 5. From this figure it is evident that ATP 
is not suitable for storage of energy, as human metabolism consumes around 75 kg (150 
moles) of ATP/day. Whole-body ATP content is approximately 0.2 moles, giving an average 
molecule of ATP a turnover rate of ~750 times per day 6. To safeguard a continuous energy 
supply on a cellular level for regeneration of ATP, humans have developed several 
complementary metabolic pathways to ensure constant availability of energy substrates for 
oxidative phosphorylation: mainly glucose, lipids, amino acids and ketones. 
2.1.2 Energy requirements and methods for estimating substrate oxidation 
The global energy requirements of humans are commonly expressed as 
TEE = BEE + AEE + DEE 
Where TEE: Total energy expenditure; BEE: Basal energy expenditure; AEE: Activity-
induced energy expenditure; DEE: Diet-induced energy expenditure 7.  
BEE represents the minimum demands of bodily maintenance functions: sustaining 
electrochemical gradients across cell membranes, nerve conduction, synthetic and 
regenerative functions, mechanical work of the cardiorespiratory system etc. 8. As this is an 
idealized state, resting energy expenditure (REE) is often used to describe EE in a resting 
postabsorptive individual. Of note, REE in ICU patients generally refers to a resting state 
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during continuous feeding. As there is a strong correlation between REE and metabolically 
active cell mass 9, it can be estimated from characteristics such as age, sex and 
anthropometric variables 10.  
The gold standard for measuring energy expenditure (EE) is by direct calorimetry. The first 
and second laws of thermodynamics state that the energy of a closed system is constant and 
that entropy will always increase over time. Accordingly, the transfer of chemical energy to 
mechanical work will eventually result in all potential and kinetic energy dissipating into heat 
(=maximal entropy). In direct calorimetry all heat radiating from a body is measured and 
quantified as EE in joules or calories per unit of time 11.   
Due to the constraints of isolating a subject from the environment to accurately measure heat 
dissipation, alternative methods have to a large extent superseded direct calorimetry in 
research and clinical practice. The theoretical basis is to measure the end-products and 
reactants of metabolism, and then calculate the corresponding energy liberated by complete 
oxidation/combustion from stoichiometric equations. This can be accomplished by ingestion 
and elimination of doubly labeled water (2H2
18O) or by measuring O2 consumption and CO2 
production from respiratory gas exchange 12. As the doubly labeled water technique has 
limited utility in critically ill patients due to rapid changes in total body water and substrate 
utilization, only the second method, indirect calorimetry, will be discussed further within this 
thesis. 
2.1.3 Indirect calorimetry: theoretical considerations 
The basis of indirect calorimetry is measuring oxygen consumption (VO2) and carbon dioxide 
production (VCO2) from respiration. The energy liberated as heat and the volume of CO2 
released from consumption of one liter of O2 during complete combustion of common energy 
substrates can be measured by burning in a bomb calorimeter. Standard values for glucose, 
fat and protein are provided in Table 1 13. 
Using these known values as constants, J.B. Weir derived a formula for calculating EE from 
gas exchange measurements in 1949 which is still widely used 14: 
𝐸𝐸 = 3.941 ∗ 𝑉𝑂2 + 1.106 ∗ 𝑉𝐶𝑂2 − 2.17 ∗ 𝑈𝑁 
Where EE: Heat output (kcal) per unit of time; VO2: O2 consumed (L); VCO2: CO2 produced 
(L); UN: Urinary nitrogen (g). This formula is often expressed as EE = Kcal/24 hours, 
VO2/VCO2 in ml/min and UN in g/24 hours: 
𝐸𝐸 = 5.68 ∗ 𝑉𝑂2 + 1.59 ∗ 𝑉𝐶𝑂2 − 2.17 𝑈𝑁 
This formula also requires quantification of urinary nitrogen (UN) loss, although omitting this 
variable will only have a minor effect on the net result within physiological ranges of UN. 
There is good agreement between EE measured by direct and indirect calorimetry in healthy 
subjects 15.  
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Table 1. Energy content of macronutrients. 
 Energy equivalent of 1L* 
O2 (kcal) 
Energy from oxidation of 
1 gram of substrate (kcal) 
Respiratory quotient 
(VCO2/VO2) 
Glucose 4.97 3.73 1.00 
Fat 4.68 9.42 0.71 
Protein (forming urea) 4.64 4.80 0.83 
Adapted from Frayn K.N. Metabolic Regulation. A Human Perspective (Wiley-Blackwell publishing 2010). Different values 
can be found in other literature depending on the type of carbohydrate, fat or protein oxidized.   
*Standard temperature pressure dry.  
 
This derivation of EE from gas exchange measurements requires several assumptions 
regarding substrate utilization: 
1. The contribution of anaerobic glycolysis to EE is quantitatively insignificant. This is 
valid under resting conditions, in the absence of regional hypoperfusion and provided 
that oxygen delivery is greater than VO2. 
2. The primary metabolic fate of reactants (energy substrates and O2) is complete 
oxidation to CO2 and water. This assumption is conditional, as several metabolic 
pathways (glycogenesis and lipogenesis) will sequester carbon atoms in the body 
without oxidizing them.  
3. Alternative substrates (ketone bodies, alcohols) do not provide a significant 
contribution to EE.   
4. The volatile carbon pool (HCO3- and CO2) is in a steady state, i.e. VCO2 reflects 
metabolic CO2 production. 
5. Urinary nitrogen excretion is constant over time and accurately reflects protein 
oxidation during gas exchange measurements.    
Although all of these conditions are unlikely to be met in an ICU patient, the resulting error 
when applied during stable clinical circumstances is likely to be small. Intermediary steps not 
accounted for by the Weir equation  (i.e. gluconeogenesis, glycogenesis or lipogenesis) will 
not affect the calculation of liberated energy over longer time frames as this depends on the 
net stoichiometry of all reactions, but may alter short-term appearance/disappearance of 
carbon and will influence net ATP generation from substrates 11, 16. 
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2.1.4 Indirect calorimetry in the ICU setting 
The interest for indirect calorimetry in the intensive care setting grew during the 1980s, as is 
evident from publications around this time evaluating metabolic monitors in mechanically 
ventilated patients 17-20. The Deltatrac Metabolic Monitor (Datex-Ohmeda, Helsinki, Finland) 
has been validated in vivo by Takala and Tissot 21, 22. It uses a mixing chamber technology 
which circumvents the potential difficulties of matching spirometry curves to measured gas 
concentrations. Due to its satisfactory performance characteristics in validation studies and 
the robust design, it has been considered the most reliable device on the market 23. 
After production of Deltatrac was discontinued, several manufacturers have been trying to 
replace it with a new generation of instruments. A common characteristic is the use of 
“breath-by-breath” technology. Gas is continuously sampled in the proximity of the 
endotracheal tube to analyze the concentrations of CO2 and O2 during inspiration and 
expiration. Gas flow is measured separately by a spirometer. The differences in gas 
concentrations over the respiratory cycle are matched to the corresponding breath and 
multiplied by flow to calculate VO2 and VCO2. As standard care has shifted towards lighter 
sedation and spontaneous breathing, the demands on software algorithms performing these 
calculations have increased. Potential benefits of breath-by-breath devices are the relative 
ease of performing measurements, the possibility for compact instrument design and rapid 
data acquisition. However, instruments marketed for use in the ICU require evaluation under 
conditions that resemble current clinical practice. For historical reasons the Deltatrac has 
been used as a reference device and clinical “gold standard”. Results from validation studies 
comparing breath-by-breath devices to Deltatrac have been mixed. McLellan evaluated the 
M-COVX (Datex-Ohmeda, Helsinki, Finland) using sequential measurements 24. They found 
a small mean difference (=bias) but wider 95% limits of agreement (LoA) for VO2 and VCO2 
(±56 and ±36 ml/min respectively). In another study of the M-COVX using simultaneous 
measurements Singer and co-workers reported even greater divergence between individual 
measurements (LoA for VO2 ±87 ml/min) 
25. Similar variations in LoA and bias have been 
observed in other validation studies comparing new instruments to Deltatrac during 
mechanical ventilation 26-28. The variable agreement raises concerns about their application in 
clinical practice and research.  
2.2 ALTERATIONS IN ENERGY METABOLISM DURING CRITICAL ILLNESS 
In health, energy homeostasis is regulated by an integration of biological signals in the 
hypothalamus. These mechanisms efficiently match energy intake to expenditure by 
influencing hunger and satiety, level of physical activity and metabolic rate at the cellular 
level 29-31. When intake exceeds metabolic demands, nutrients are stored as glycogen and 
triglycerides from the actions of insulin. During starvation endogenous energy stores are 
mobilized by gluconeogenesis and lipolysis from the actions of counterregulatory hormones 
such as glucagon, adrenaline, noradrenaline, cortisol and growth hormone (GH) 13. Protein 
degradation will indirectly contribute to energy metabolism from amino acid oxidation, but 
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inevitably results in a loss of functional tissues as there is no repository for amino acids in the 
body.      
Patients admitted to the ICU have often been exposed to some form of insult (tissue trauma, 
infection, ischemia-reperfusion etc.) which leads to inflammation. Inflammatory mediators in 
conjunction with the neurohormonal response to multiple physiological stressors such as 
pain, hypotension, hypovolemia and hypoxia trigger the metabolic alterations commonly 
described as “the metabolic stress response” 32. This is characterized by: 
• Upregulation of major catabolic pathways for glucose, lipids and protein. 
• An increased turnover of energy substrates and protein. 
• Altered utilization of macronutrients. 
• A decreased sensitivity to the anabolic actions of insulin. 
• Differential regional capacity for aerobic metabolism 33. 
• Impaired behavioral signals for volitional nutrient intake 34, 35.   
These changes were rudimentarily described almost a century ago by Sir David Cuthbertson 
as the “flow” response to traumatic injury 36. Our current understanding of this phenomenon 
is mainly based on small physiological studies in animal models or patients of variable age, 
co-morbid conditions, acute pathologies and duration of hospitalization. In addition, these 
findings have been published over the course of several decades, and treatments that may 
attenuate the metabolic response (surgical methods, sedation, nutritional practices, 
physiotherapy etc.) will be very different depending on the setting in which a study was 
performed. Any general statements should therefore be viewed as abstractions with a high 
degree of uncertainty regarding the implications for individual patients in a modern ICU 
setting. With this caveat, the following sections will briefly summarize the alterations in 
energy and protein metabolism during critical illness. 
2.2.1 Glucose metabolism 
Hyperglycemia is common in ICU patients 37. Plasma glucose may be raised either from 
increased endogenous production or impaired uptake. Both mechanisms contribute to the 
alterations seen during critical illness, resulting in a higher glucose turnover rate.  
The main driver behind hyperglycemia in critical illness is an increase in gluconeogenesis 38, 
39. This is mediated by the actions of cytokines and counterregulatory hormones 40. Plasma 
concentrations of cortisol, GH, catecholamines and glucagon are all increased during critical 
illness 41-44. In contrast to healthy volunteers 45, 46, multiple observations indicate that the 
increased rate of gluconeogenesis in critical illness is only partially attenuated by parenteral 
glucose infusions 47-51. It may be suppressed by the administration of high doses of exogenous 
insulin 49, 51-54.   
Insulin-mediated glucose uptake, primarily in skeletal muscle, is impaired during critical 
illness 53-55. In contrast, data from animal models of sepsis indicates that non-insulin mediated 
glucose uptake may be increased in macrophage-rich tissues 53, 55. The mechanisms of insulin 
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resistance during critical illness are multifactorial and influenced both by endocrine signals 
and inflammatory mediators 56. Plasma insulin levels are increased compared to healthy 
controls but the ratio of insulin/glucagon is reduced 41, 49, 54, 57.   
Whole-body glucose oxidation may not be impaired 39, 48. However, the higher turnover rate 
during critical illness necessitates an increase in non-oxidative glucose disposal. This may be 
facilitated by substrate cycling where three-carbon metabolites of glycolysis and 
gluconeogenic amino acids are exported from peripheral tissues and reconstituted to glucose 
by the liver 48, 58.  
The net effect of these alterations is to increase the availability of glucose to tissues with 
insulin-independent uptake. This is potentially an adaptive response, to improve energy 
delivery toward organ functions vital to short-term survival 59, 60. 
2.2.2 Lipid metabolism 
Fat stores are an important source of energy during critical illness. Studies of free fatty acid 
(FFA) kinetics in sepsis, burns, trauma and experimental models of systemic inflammation 
consistently demonstrate an elevated rate of appearance of FFAs and glycerol, indicating an 
increased rate of lipolysis 58, 61-64. This appears to be mediated by the actions of 
catecholamines and proinflammatory cytokines 65, 66. Adipose tissue of septic patients is 
resistant to the actions of insulin 67.  
The rate of endogenous FFA mobilization may exceed energy expenditure and likely 
provides the majority of energy requirements in a fasted state 64, 68. Kinetic studies show 
diverging results regarding the potential of exogenous nutrients to suppress lipolysis: it may 
be attenuated or persist despite supplementation of calories 48, 61, 62, 69. Body composition 
studies demonstrate a loss of adipose tissue over time in patients with energy provision lower 
than expenditure 70, 71. De novo lipogenesis in critically ill patients may also be induced by 
high exogenous glucose loads 50.   
The preferential oxidation of lipids or glucose appears to depend on the relative availability of 
exogenous substrates 50, 68, 72. Studies using indirect calorimetry to calculate substrate 
oxidation rates have observed low respiratory quotient (RQ) values indicative of predominant 
lipid oxidation 73, but this is not a ubiquitous finding 74. Mitochondrial alterations may also 
influence the utilization of lipids as a fuel source. Acquired carnitine deficiency can impair 
transport of FFAs across the mitochondrial membrane 75, and the expression of enzymes for 
beta oxidation are depressed in skeletal muscle of critically ill patients 76.   
2.2.3 Energy expenditure during critical illness      
There is poor agreement between predictive equations and measured REE in critically ill 
patients, indicating a greater inter-subject variability of metabolic rate compared to a healthy 
population 77-81. It has long been held that critical illness is a hypermetabolic state, i.e. that the 
basal metabolic rate is higher than that predicted by simple population characteristics 82, 83. 
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Physiological factors such as fever, increased substrate cycling, and synthetic functions 
associated with the host response to stress and inflammation provide a theoretical basis for 
this generalization. Energy expenditure is also influenced by common ICU therapies 84, 85.  
The average metabolic rate reported in studies of ICU patients is variable. A number of small 
studies measuring REE by indirect calorimetry in the context of sepsis, multi-organ failure, 
and trauma have observed a metabolic rate >30 kcal/kg/day 74, 86-90, or a more moderate 
increase between 25-30 kcal/kg/day 91-95. Other studies found an average REE between 20-25 
kcal/kg/day 96-99. The largest observational study of REE in a modern ICU setting by Zusman 
and colleagues found a mean REE of 24 kcal/kg/day in a sample of 1440 patients 81. Studies 
that report correlations between morbidity or mortality and energy expenditure indicate that 
sicker patients and non-survivors have a lower REE 86, 90, 93, 100, but this is not a universal 
observation 89. Interpretations of these findings are limited by potential survivorship bias and 
confounders such as age and physical activity.  
2.2.4 Energy balance during critical illness 
In health, energy balance is when caloric intake equals total energy expenditure over time. As 
a critically ill patient may have significant endogenous substrate mobilization even during the 
provision of exogenous nutrients, it is difficult to determine when energy balance occurs in an 
ICU setting.  
The importance of this concept during critical illness is a subject of ongoing contention. 
Several observational studies have reported positive associations between accumulated 
energy deficits and mortality, nosocomial infections and other adverse outcomes 101-104. Only 
a small proportion of the centers in these studies calculated energy balance from indirect 
calorimetry. A recent single-center observational study of nearly 1200 mechanically 
ventilated patient identified a U-shaped relationship between % intake/measured REE and 
mortality, with the lowest odds ratio at 70% 100. The authors interpret this as a signal of harm 
from both under- and overfeeding. Causal mechanisms for these observed relationships have 
not been clearly elucidated, although findings of some studies point toward the importance of 
protein intake and the attenuation of protein catabolism by non-protein calorie intake 105. An 
inverse correlation between nutritional delivery and mortality could also be an 
epiphenomenon to illness severity. Gastrointestinal dysfunction is an independent predictor of 
poor outcome, and feeding intolerance may reflect the degree of multiorgan failure in ICU 
patients 106.       
During the last decade, several large multicenter randomized controlled trials (RCTs) have 
been conducted to investigate the relationship between energy delivery and clinical outcomes 
in ICU patients. The inclusion criteria, therapeutic interventions, control groups and outcome 
measures of the largest trials to date are summarized in Table 2 107-111. The main differences 
are the underlying hypotheses (that an exogenous energy deficit is either harmful or 
beneficial) and the route of energy delivery (enteral or parenteral). Although there are 
potentially important physiological differences between enteral nutrition (EN) and parenteral 
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nutrition (PN) with regard to the endocrine response, nutrient uptake and gastrointestinal 
mucosal and immune function 112, two recent multicenter RCTs investigating early exclusive 
use of EN or PN in ICU patients did not find any differences in mortality, infectious 
complications or ICU length of stay 113, 114. The results from the trials listed below may 
therefore be considered from a perspective of energy provision rather than route of delivery.  
Table 2. Summary of study characteristics in five multi-center randomized controlled trials 
investigating energy delivery in critically ill patients. 
 Patients (N) Population Intervention Control Primary outcome 
Casaer et al 107 4640 Adult ICU patients 
with NRS ≥3 
Late initiation of 
PN (day 8) to 
meet energy 
target 
Early initiation of 
PN (day 3) to 
meet energy 
target 
Time to ICU 
discharge 
Rice et al 108 1000 Adult ICU patients 
with ALI & 
mechanical 
ventilation 
Trophic EN day 1-
6 
EN to meet 
energy target from 
day 1 
Ventilator-free 
days to day 28 
Doig et al 109 1372 Adult ICU patients 
with short term 
contraindication to 
EN 
PN to meet 
energy target after 
inclusion 
Standard care Death by day 60 
Arabi et al 110 894 ICU patients with 
enteral feeding 
<48 hours from 
admission 
Permissive 
underfeeding (40-
60% of energy 
target with protein 
supplementation) 
Standard care 
(70-100% of 
energy target) 
90 day all-cause 
mortality 
Chapman et al 111 3957 Adult 
mechanically 
ventilated ICU 
patients initiating 
EN  
Energy-dense 
(1.5 kcal/ml) EN 
formula with 
volume target 
Standard (1 
kcal/ml) EN 
formula with 
volume target 
90 day all-cause 
mortality 
ALI: Acute lung injury; EN: Enteral nutrition; ICU: Intensive care unit; NRS: Nutrition risk score; PN: Parenteral nutrition.  
 
 16 
None of the trials found a benefit in mortality or major morbidity to any of these strategies. 
The only trial that detected harmful effects (a higher rate of infections and longer ICU stay) 
from early increased energy delivery used supplemental parenteral nutrition with high 
glucose content in combination with tight glycemic control with insulin, mainly in elective 
cardiothoracic surgical patients 107. The trials that included a long-term follow-up did not 
identify any difference in physical function between intervention and control groups 115, 116.  
Only a few clinical trials have investigated the utility of matching intake to measured energy 
expenditure during critical illness, with mixed findings 117-119. Heidegger and colleagues 
reported a lower rate of hospital-acquired infections in patients receiving supplemental 
parenteral nutrition to reach 100% of their energy target from day four in ICU 118. Of note, 
this result did not remain statistically significant when the event rate during the entire study 
period was analyzed, and only 65% of patients had nutritional targets set by indirect 
calorimetry. Singer and co-workers randomized 130 patients to a tight-calorie control group 
using daily REE measurements or standard care. The intervention group received 
significantly more daily calories, primarily as parenteral nutrition. There was no difference in 
the primary outcome of hospital mortality using intention-to-treat analysis. The recently 
published EAT-ICU trial also assessed individualized nutrition in mechanically ventilated 
ICU patients, using daily indirect calorimetry and nitrogen balance to guide therapy in the 
intervention group. 203 patients were recruited with a sample size determined from the least 
relevant change in the primary outcome of physical quality of life six months after 
randomization. Despite achieving significant separation in energy and protein balance 
between groups, no differences in primary or secondary outcome measures were observed. 
In summary, there is insufficient evidence to support a clear signal of benefit or harm over a 
broad range of energy provision in a general population of critically ill patients. 
2.3 PROTEIN METABOLISM 
2.3.1 Muscle protein regulation in health 
Proteins are the macromolecules performing mechanical work in cells and serve a multitude 
of other vital functions 6. The synthesis of proteins from amino acids by transcription of DNA 
is a fundamental step in the regulation of cellular function. As all proteins have other primary 
functions than as a fuel source for oxidative metabolism, there are no deposits of stored 
amino acids in the human body comparable to glycogen and adipose tissue for glucose and 
fat. To ensure availability of amino acids for synthetic functions in all organs, these are in a 
constant state of turnover from breakdown and synthesis of proteins. The two main pathways 
for protein degradation are the ubiquitin-proteasome system and autophagy 120. These also 
protect against the accumulation of dysfunctional or damaged proteins which threaten cell 
function 121. Most of the recycling occurs within cells, but amino acids are also exported to 
the bloodstream. After uptake by other organs they have three possible metabolic fates: 
integration into new proteins, modifications of functional groups into other amino acids, or 
catabolism. As dietary amino acids contribute to the whole-body pool a net oxidation rate 
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roughly equal to intake (∼1 g/kg/day) is necessary for homeostasis. The turnover rate of body 
protein is approximately fourfold that of daily nutritional requirements 13.   
Skeletal muscle contains 50-75% of total body protein 122. It is therefore a major potential 
source of free amino acids. Skeletal muscle protein balance is regulated by a complex 
interplay of anabolic and catabolic signals (insulin, IGF-1, cortisol), inflammatory mediators, 
amino acid availability, and loading conditions. These factors interact through intracellular 
second messengers regulating gene transcription and proteolysis. The protein complex 
mammalian target of rapamycin complex-1 (mTORC-1) is the main site of integration for 
anabolic signals and sensing of nutritional status 123. Bed rest and caloric restriction have 
been demonstrated to induce a negative protein balance in healthy volunteers, while 
resistance training, increased protein intake, branched-chain amino acids and insulin can 
improve protein balance and promote skeletal muscle anabolism 124-128. 
2.3.2 The implications of critical illness on muscle structure and function 
The loss of lean body mass that accompanies severe acute illness has been appreciated for 
over a century. As improvements in health care result in higher rates of survival after critical 
illness, the burden of long-term functional disability and muscle weakness in survivors has 
generated increasing interest 129. ICU-acquired weakness is common and correlates with 
severity of illness. The cause is multifactorial; impaired nerve conduction and injury, 
mitochondrial dysfunction, inflammatory changes in muscle architecture, altered membrane 
ion conduction and increased proteolysis have all been implicated as contributing factors 33, 
130.  
Studies investigating whole-body protein kinetics in various states of critical illness have 
observed an increased rate of synthesis coupled with a larger increase in breakdown, resulting 
in a net negative balance 131-133. These changes are heterogeneously distributed between 
different organ systems. Synthesis appears to be upregulated in the splanchnic, hepatic, 
reticuloendothelial and innate immune system 134. Skeletal muscle catabolism provides the 
main source of amino acids for the increased demands of the acute phase response. Biopsies 
from skeletal muscle in sepsis show normal synthetic function, increased breakdown and 
reduced protein content 135-138. This is consistent with lower limb arteriovenous balance 
studies in sepsis and burns where leg muscle amino acid efflux is markedly increased 137, 139. 
Radiological body composition studies during critical illness also reveals a loss of around 
0.5-1% of skeletal muscle mass per day  70, 71, 140. The loss of muscle protein appears to be 
most pronounced in the early phase of critical illness 138. Dos Santos and colleagues recently 
conducted a long-term follow up of these alterations in 11 patients requiring mechanical 
ventilation for >7 days. Loss of muscle mass persisted at six months in the majority after 
hospital discharge, but with normalization of proteolytic activity and mitochondrial content 
141.  
Although there are many potential factors confounding the association between muscle loss 
and functional status, it has been hypothesized that interventions to ameliorate catabolism 
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may reduce physical disability and improve quality of life in ICU survivors 142. In healthy 
subjects there are three main ways to stimulate skeletal muscle anabolism: hormonal therapy, 
exercise, and nutrition. GH can reduce muscle wasting in ICU patients but the interest for 
anabolic hormones has been tempered by trials demonstrating excess mortality from the 
administration of GH during critical illness 143, 144. Promoting muscle use by physical therapy 
or passive electrical stimulation may also alter the proteolytic response 145. The following 
section will review the effects of nutritional interventions, in particular protein 
supplementation, on protein catabolism and muscle loss. 
2.3.3 The effects of calorie and protein supplementation on protein 
catabolism in critical illness 
The physiological effects of protein supplementation in ICU patients have mainly been 
investigated on a whole-body level. The most widely used technique to assess changes in 
body protein content is nitrogen balance, which is performed by measuring nitrogen losses in 
relation to intake. Several studies published up to 2012 investigating different levels of 
protein intake are summarized in a review by Hoffer and Bistrian, indicating that increasing 
daily protein intake up to 2-2.5 g/kg/day improves nitrogen balance 146. Despite its 
widespread application in critical care research the nitrogen balance technique has several 
limitations in this setting. Accurate quantification of nitrogen losses is challenging, and the 
long-term steady state conditions required for this method to be valid are often violated 147, 
148. Whole-body protein kinetics can also be assessed by isotope tracer techniques that require 
a shorter period of stable measurement conditions (discussed further in Chapter 5). Tracer 
investigations in critically ill patients have also demonstrated an improvement in whole-body 
protein balance from increased provision of exogenous calories and/or protein 149-151.  
However, changes in whole-body protein balance are not necessarily reflected in preservation 
of skeletal muscle mass. A recent systematic review of the association between nutrition and 
muscle loss during critical illness highlighted that existing studies are small, include a 
heterogenous group of patients, use different methods to assess muscle loss and have large 
variations in macronutrient dose delivery 152.  One observational study of ICU patients found 
a positive correlation between protein intake and muscle loss estimated by change in rectus 
femoris cross-sectional area over time 138. This was a post-hoc finding and susceptible to the 
multiple comparisons problem. Muscle biopsies from a study nested within a large RCT of 
early vs late parenteral nutrition did not show a correlation between myofiber density and 
macronutrient deficit 153. One pilot RCT of increased protein and energy delivery to ICU 
patients found a statistically significant difference in quadriceps muscle layer thickness from 
higher protein (1.2 vs 0.75 g/kg/day) and energy (21 vs 18 kcal/kg/day) intake 154. This did 
not translate to improvements in functional outcomes. Ferrie and colleagues found similar 
improvements in muscle mass in patients receiving 1.1 vs 0.9 g/kg/day of protein during ICU 
stay but no difference in handgrip strength 155. Other small-intermediate size RCTs 
investigating the effects of increased protein and energy intake on functional disability have 
not found any benefit to higher macronutrient delivery 119, 156. This is consistent with long-
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term follow-ups of functional outcomes in patients from large multi-center RCTs 
investigating higher vs lower energy provision, where mortality and morbidity were the 
primary outcome measures 115, 116. 
2.3.4 Protein supplementation and ICU outcomes 
Several observational studies have found an inverse correlation between protein intake during 
ICU stay and mortality 100, 102, 157, 158. Low skeletal muscle mass on admission is also 
associated with an increased risk of death in ICU 159. A possible interpretation of these 
findings is that a reduced availability of amino acids may impair recovery. Despite a 
physiological rationale for exogenous protein delivery during critical illness, there is limited 
evidence to support a causal relationship with mortality and organ dysfunction in the ICU. 
Recent iterations of nutritional guidelines recommend protein dosing between 1.2-2 g/kg/day 
based on very low quality of evidence 160, 161. Currently there are no published clinical trials 
of higher vs lower protein targets in ICU patients adequately powered for mortality. Doig and 
co-workers have conducted the largest RCT of amino acid supplementation in ICU patients to 
date 162. In 474 patients randomized to amino acid supplementation up to 100 grams/day or 
standard care, the investigators did not find any difference in duration of renal dysfunction or 
90-day mortality. A post-hoc analysis of the trial identified a lower risk of death associated 
with amino acid supplementation in patients with normal renal function at baseline, but this 
result should only be interpreted as hypothesis-generating 163. Other clinical trials of protein 
supplementation previously referenced have not detected any differences in organ 
dysfunction or death as found in observational studies. It has also been postulated that an 
increased systemic availability of amino acids may adversely affect outcomes through 
inhibition of autophagy 164. While this hypothesis is supported by some preclinical 
observations and surrogate outcome measures, the relevance of these findings is still unclear. 
2.4 TIME COURSE OF METABOLIC ALTERATIONS AND PATIENT 
HETEROGENEITY    
The “ebb” and “flow” responses to injury described by Cuthbertson provide a conceptual 
framework for changes in metabolic derangements over time. The most recent iteration of the 
European clinical practice guidelines for ICU nutrition have adopted this terminology but 
divide the “flow” phase into an acute and post-acute period 160. The post-acute phase is 
assumed to either resolve in clinical improvement or a state of persistent catabolism (Fig. 1). 
Beyond avoiding early overfeeding, the authors make no specific recommendations regarding 
nutritional support based on the trajectories described.  
However, changes in metabolism over time could hypothetically have implications for 
nutritional and metabolic therapies. The physiological alterations during the prolonged post-
acute phase is an evolving area of research and remain to be fully characterized. A recent 
consensus statement from an expert group on ICU nutrition proposes that stratification by 
clinical “phenotypes” or metabolic markers may provide a basis for individualized care in the 
future 165. This section will briefly explore our current knowledge in this expanding field.      
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Figure 1. A conceptual model of temporal changes in the metabolic response to critical illness. 
Adapted from ESPEN guideline on clinical nutrition in the intensive care unit 160. 
Recent years have seen an increasing focus on describing characteristics of patients who fail 
to recover from critical illness. This group carries a disproportionate burden in terms of 
morbidity, mortality and ICU resource allocation 166. Several definitions or subtypes of 
“chronic critical illness” have been proposed based on duration of organ support 167, 
performance of outcome prediction models over time 166, 168, or concurrent features of chronic 
inflammation, adaptive immune dysfunction and muscle catabolism (Persistent Inflammation 
Immunosuppression Catabolism Syndrome or PIICS) 169. Trends in C-Reactive Protein and 
Urea/Creatinine ratio have been investigated as markers to identify patients with persisting 
catabolism and muscle loss 170, 171.  
Of interest, a recent observational study of muscle protein kinetics in 20 ICU patients found 
that muscle protein balance normalized over time from an increase in protein synthesis after 
30-40 days of ICU stay 172. This result stands in contrast to notions of persistent catabolism in 
patients with a prolonged course of critical illness. Another investigation of muscle mass 
assessed by rectus femoris ultrasound found a progressive loss of skeletal muscle during the 
first 14 days in 17 ICU patients 173. Indices of catabolism (urinary nitrogen loss and 3-
methylhistidine) remained elevated despite reductions in CRP. The rate of change in muscle 
depth appears to decrease over time. The small number of patients and heterogeneity in these 
studies illustrates the challenge to delineate general characteristics or “phenotypes” of 
patients with prolonged ICU stay. 
2.5 SUMMARY 
Catabolism and muscle wasting are well-recognized problems in ICU patients. Protein 
supplementation and avoiding long-term energy deficits may ameliorate these detrimental 
effects. Clinical trials have thus far failed to demonstrate improved outcomes from standard 
or individualized levels of macronutrient intake in a general ICU population, raising the 
question if strict energy or protein balance is relevant to recovery. An optimal strategy for 
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nutritional support over a prolonged course of ICU stay and convalescence remains to be 
defined. Physiological investigations are important in developing hypotheses for future 
intervention studies.  
A better understanding of macronutrient utilization during critical illness may be obtained 
from available techniques in metabolic research. Analysis of substrate kinetics using stable 
isotope tracers provides additional information about the physiological impact of nutritional 
interventions. Changes in energy metabolism over time can be assessed using indirect 
calorimetry, but the technical challenges of accurate measurements in an ICU setting require 
validations of new equipment before use in research or clinical practice.    
  
 22 
3 AIMS 
The overall aims of this thesis were to investigate the measurement properties of instruments 
used to determine energy metabolism in ICU patients, and to better characterize the 
utilization of exogenous macronutrients during critical illness. The aims of individual studies 
are listed below: 
• To quantify agreement in gas exchange measurements by indirect calorimetry in 
mechanically ventilated ICU patients between commercially available instruments 
and a reference device (studies I and II). 
• To assess if a supplemental infusion of intravenous amino acids sustains an 
improvement in whole-body protein balance in critically ill patients over 24 hours 
(study III).  
• To investigate if the provision of full-dose compared to half-dose enteral nutrition, 
using energy targets determined by indirect calorimetry, results in an improved 
whole-body protein balance in critically ill patients with established enteral feeding 
(study IV). 
• To monitor the effects of a higher provision of amino acids or protein on amino acid 
oxidation, plasma amino acid concentrations and serum urea levels in critically ill 
patients (studies III and IV). 
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4 STUDIES OVERVIEW 
4.1 DESIGN AND EXPERIMENTAL PROTOCOLS 
In study I, we compared measurements of resting energy expenditure in mechanically 
ventilated ICU patients between Deltatrac metabolic monitor (Datex-Ohmeda, Helsinki, 
Finland) and two other instruments: CCM Express (Medgraphics Corp, St Paul, Minneapolis, 
USA) and Quark RMR (Cosmed, Rome, Italy). The protocol was adapted from a previous 
study of indirect calorimetry in spontaneously breathing healthy subjects 174. Measurements 
were performed in sequence with all three instruments during a 10-20 minute period under 
resting conditions with no changes in the rate of nutrition provided. The order was 
determined by simple randomization from drawing sealed notes. At the end of the sequence a 
fourth measurement was performed with the first device used. The average values from 
measurements 1 and 4 was used for results to compensate for changes in metabolic rate and 
clinical conditions over time. 
In study II, gas exchange measurements (VO2 and VCO2) were performed with three 
different instruments in mechanically ventilated ICU patients. Comparisons of agreement 
were made between a reference method (Deltatrac II metabolic monitor) and two 
commercially available devices designed for use in an ICU setting: Quark RMR and E-
sCOVX (GE Healthcare, Helsinki, Finland). All instruments were connected to the ventilator 
circuit and measurements performed simultaneously with Deltatrac and one other study 
device at a time for 20 minutes after a mandatory stabilization period. The order of 
comparisons was determined by simple randomization.     
In study III, the effects of a 24-hour supplemental amino acid infusion (Glavamin, Fresenius-
Kabi) on whole-body protein balance was investigated in critically ill patients. A previous 
study by our research group found that a 3-hour amino acid infusion improved whole-body 
protein balance in critically ill patients, without increasing amino acid oxidation 149. The goal 
of the present study was to investigate if this response could be sustained for a longer period. 
The primary outcome was change in whole-body protein balance over time, assessed with a 
stable isotope tracer method. Secondary outcomes measures were changes in plasma amino 
acid concentrations, amino acid oxidation rate and serum urea concentration.  
In study IV, the effect of full-dose versus half-dose EN on whole-body protein balance was 
investigated in critically ill patients with established enteral feeding and calorie delivery close 
to measured energy expenditure. Patients served as their own controls in a cross-over design 
and were randomized to an initial allocation of 50 or 100% rate of ongoing EN for 24 hours. 
At the end of this period whole-body protein balance was assessed using a stable isotope 
tracer protocol similar to that in study III. The rate of EN was then changed to the alternate 
treatment allocation, and a new measurement of protein kinetics performed at the end of the 
second 24-hour period. Secondary outcome measures included plasma amino acid profile, 
indices of increased amino acid oxidation as in study III and splanchnic extraction of 
phenylalanine. 
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Additional details on the experimental protocols can be found in the published papers and 
manuscript.  
Connections of indirect calorimeters to the ventilator circuit in studies I and II are described 
in Fig. 2 and 3. Schematic illustrations of the protocols for nutrition and stable isotope tracers 
in studies III and IV are depicted in Fig. 4 and 5. 
 
Figure 2. Connection points of Quark RMR, CCM Express and Deltatrac to ventilator circuit in 
study I. Only one instrument connected at a time during the study protocol. 1. Dräger Evita XL ventilator; 2. Fraction of 
inspired O2 sampling to Deltatrac; 3. Mainstream capnography; 4. Heat and moisture exchange filter; 5. Quark RMR gas 
sampling line; 6. CCM Express pneumotach flowmeter; 7. CCM Express gas sampling line; 8. Quark RMR turbine flowmeter.  
 
Figure 3. Connection of Quark RMR, E-sCOVX and Deltatrac II to ventilator circuit in study II. All 
instruments connected simultaneously during the study protocol. 1. Dräger Evita XL ventilator; 2. Fraction of inspired O2 
sampling to Deltatrac; 3. E-sCOVX pneumotach flowmeter; 4. Mainstream capnography; 5. Heat and moisture exchange filter; 6. 
E-sCOVX gas sampling line; 7. Three-way stopcock; 8. Quark RMR gas sampling line;  9. Quark RMR turbine flowmeter.   
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Figure 4. Study protocol of study III (not to scale). IV: intravenous; Phe: Phenylalanine; T: Time; Tyr: Tyrosine   
 
Figure 5. Study protocol of study IV (not to scale). EN: Enteral nutrition; IV: intravenous; Phe: Phenylalanine; T: 
Time; Tyr: Tyrosine. 
4.2 SUBJECTS AND SETTING 
All studies were performed in the ICU of Karolinska University Hospital Huddinge, a tertiary 
referral hospital in the greater Stockholm area. The hospital has a large emergency 
department and is a regional center of excellence for major upper abdominal surgery, 
abdominal solid organ transplantation and hematopoietic stem cell transplantation. The ICU 
is a mixed surgical-medical unit with a 12-bed capacity and a mean 30-day crude mortality of 
20% 175. The unit occasionally admits pediatric patients but is not a dedicated pediatric ICU. 
Extracorporeal membrane oxygenation, neurosurgery and cardiothoracic surgery are not 
available on-site. 
In studies I and II, adult (≥18 years of age) ICU patients with invasive mechanical ventilation 
and a constant rate of parenteral and/or enteral nutrition were eligible for inclusion. Exclusion 
criteria were i) anatomical air leaks (bronchopleural fistulas, pneumothorax etc.) or gas leaks 
in the ventilator circuit of >10% of minute volume, ii) FiO2 of ≤0.5 (study I) or ≤0.6 (study 
II), iii) a respiratory rate of >35 (study II) and iv) lack of informed consent. 
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In study III, adult ICU patients admitted to the unit during the recruitment period were 
screened for inclusion. The rate of enteral or parenteral nutrition therapy was not to be altered 
during the study period. Exclusion criteria were i) renal replacement therapy, ii) ongoing 
resuscitation for circulatory instability, iii) patient unlikely to complete protocol due to 
planned investigation/procedures/transfers etc., iv) patient in hospital for >2 weeks prior to 
screening for inclusion, v) lack of arterial line for blood sampling and vi) no informed 
consent.  
In study IV, adult ICU patients with invasive mechanical ventilation (FiO2 ≤0.6) and 
established enteral feeding (enteral calories ≥80% of energy target as determined by indirect 
calorimetry) could be included. Exclusion criteria were i) if extubation, withdrawal of life 
support, interruptions in enteral feeding or patient transfer was expected during the study 
period, ii) lack of central venous or arterial catheters for blood sampling, iii) volume 
resuscitation with crystalloid or blood products during the measurement periods and iv) lack 
of informed consent.  
The characteristics of patients included in Studies I-IV are listed in Table 3.  
Table 3. Patient characteristics studies I-IV. 
 Study I Study II Study III Study IV 
Number of patients (N) 24 22 12 6 
Sex (male/female) 15/9 17/5 8/4 5/1 
Age 61 (36-79) 61 (18-83) 65 (47 – 74) 58 (28 – 73) 
BMI (kg/m2) 25.5 (18.3-43.1) 25.3 (16.5-51.5) 27.9 (22 – 38.9) 27.1 (19.5 – 40.7) 
SAPS III 61(43-77) 67 (38-100) 52 (34 – 68) 83 (45 – 108) 
Values are given as median (range). BMI: Body mass index; SAPS: Simplified acute physiology score. 
4.3 ETHICAL CONSIDERATIONS 
All studies were approved by the regional ethics committee (Regionala 
etikprövningsnämnden i Stockholm) and conducted in accordance with the principles stated 
in the World Medical Association Declaration of Helsinki 176. Critically ill patients are in 
many ways a “vulnerable group”: they experience the psychological burden of being in a life-
threatening situation and often suffer from cognitive impairments both from acute illness and 
sedative drugs. Verbal communication may also be impaired by mechanical ventilation. All 
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these factors compromise their ability to make informed decisions and communicate their 
intentions about health care choices or participation in clinical research. Performing clinical 
studies in ICU patients requires a balance between patient autonomy, the risks of 
participation and the potential benefits that may be gained for the individual patient or 
vulnerable group as a whole. In all four studies informed consent was primarily sought from 
the patient, and in the case where the patient was not able to provide consent, the nearest 
relative. If consent was provided by proxy, direct consent was sought as soon as possible. 
Patients or their relatives were informed both orally and in writing about the study aims, 
procedures, potential risks and benefits, funding sources and that consent could be withdrawn 
at any time.  
In studies I and II there were no potential benefits for the individual patient from 
participation. For ICU patients as a group, the clinical validation of measurement instruments 
is important as the results from these devices will influence treatment decisions in routine 
care. Although there are no demonstrated benefits to measuring energy expenditure during 
critical illness, this practice is recommended by the major professional societies for ICU 
nutrition in North America and Europe 160, 161. Indirect calorimetry was also routine clinical 
practice at the study site. The risks to patient were considered low, as measurements are non-
invasive and only require connection of instruments to the ventilator circuit. Patients 
dependent on high mean airway pressures to avoid alveolar collapse could potentially be 
harmed by temporary disconnection from the ventilator, but as high FiO2 was an exclusion 
criterion this generally precluded participation of patients with severe acute respiratory 
distress syndrome. 
For study I, the Quark RMR and CCM Express devices were provided by the manufacturers 
for the duration of the study period. In study II, GE Healthcare provided an E-sCOVX unit 
for study purposes. The Quark RMR device in study II was owned by the study site. A data 
sharing agreement was drafted with GE Healthcare and a non-disclosure agreement signed by 
the primary author and study sponsor regarding proprietary technical details of the 
instrument. The commercial interests involved provided no financial support or remuneration 
for the studies and did not have any mandate over study design, data analysis, drafting of the 
manuscripts or the decision to submit for publication.    
In studies III and IV patients were exposed to clinical interventions that deviate from routine 
care at the study site: a 24-hour period of intravenous amino acids and low-dose 
(“hypocaloric”) EN, respectively. Neither of these interventions have any proven positive or 
negative effects on patient-centered outcomes 110, 162. Both the higher amino acid dose from a 
supplemental infusion and hypocaloric EN fall within limits of what is considered standard 
practice in other regions 161. The stable isotope tracers infused for measurements of protein 
kinetics are not associated with any known health risks. Both study protocols require 
additional blood samples, but these were drawn from catheters already sited for clinical 
purposes. The total volume of blood drawn for study purposes was 40 (study III) and 60 ml 
(study IV).   
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5 METHODS 
5.1 INDIRECT CALORIMETRY 
5.1.1 Indirect calorimetry in mechanically ventilated patients 
Performing indirect calorimetry in mechanically ventilated ICU patients is complicated by the 
common occurrence of high airway pressures, humidity, circuit leaks, high or variable 
respiratory rates and supplemental oxygen. Certain restrictions imposed on the conditions of 
measurements are essential to maintain accuracy, mainly a fraction of inspired oxygen (FiO2) 
≤0.6. As determining the difference in oxygen content between inspired and expired gas 
requires a highly accurate measurement of bidirectional flow, the so-called Haldane 
transformation is commonly applied. Assuming that there is no exchange of N2 in the lungs 
and that the CO2 content of ambient air is negligible, then: 
(1 − 𝐹𝑖𝑂2) ∗ 𝑣𝑖 = (1 − 𝐹𝑒𝑂2 − 𝐹𝑒𝐶𝑂2) ∗ 𝑣𝑒 
    
Where vi : inspired volume; ve: expired volume; FeO2: expired fraction of O2; FeCO2: expired 
fraction of CO2. As: 
 𝑉𝑂2 =  𝐹𝑖𝑂2 ∗ 𝑣𝑖 − 𝐹𝑒𝑂2 ∗ 𝑣𝑒 
Vi from the first equation can be substituted into the second equation and rearranged further: 
𝑉𝑂2 =
((𝐹𝑖𝑂2 − 𝐹𝑒𝑂2) − (𝐹𝑖𝑂2 ∗ 𝐹𝑒𝐶𝑂2))
(1 − 𝐹𝑖𝑂2)
∗ 𝑣𝑒 
  
This equation only requires measurement of expiratory volumes, but as FiO2 is in the 
denominator it behaves non-linearly at higher fractions. A similar equation can also be 
derived for VCO2. 
5.1.2 Deltatrac metabolic monitor 
The Deltatrac metabolic monitor measures respiratory gas exchange with a mixing chamber 
design. It can be used both for non-intubated patients with a canopy and during invasive 
mechanical ventilation. O2 and CO2 concentrations are measured with a differential 
paramagnetic and infrared sensor respectively. It does not measure flow of inhaled/exhaled 
gas directly, instead deriving this from other parameters. The principles for deriving VO2 and 
VCO2 are illustrated in Fig. 6. FiO2 is sampled in the inspiratory limb of the ventilator, and all 
expiratory gas from the patient is channeled into a 4-liter mixing chamber where FeO2 and 
FeCO2 are measured. Gas samples pass through specialized tubing where the partial pressure 
of water vapor equilibrates to that in ambient air. The gas in the mixing chamber is drawn 
into a separate chamber by the Venturi effect and diluted by a constant flow of room air (Q), 
usually 40 L/min in the adult configuration. The concentration of CO2 in the diluted gas 
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mixture (FCO2) is measured downstream. VCO2 is calculated from the product of FCO2 and 
Q. RQ, the quotient of VCO2 and VO2, can be calculated from gas fractions alone using the 
Haldane transformation. VO2 is then derived from VCO2 and RQ. 
A benefit of this design is that flow measurements and the synchronization of gas 
concentrations and volumes of each breath are not required. As gas concentrations in the 
mixing chamber are averaged every 30-60 seconds, the effects of temporary irregular 
breathing patterns like coughing are dampened.  
In study I, the original Deltatrac metabolic monitor was used. For study II, a Deltatrac II unit 
was used due to technical difficulties with the first device. The measurement principles for 
these devices are identical but the latter version could export output data in digital format.   
 
Figure 6. A schematic illustration of the Deltatrac I/II principles of measurement. FCO2: Fraction of 
CO2 in expired gas diluted by constant flow generator; FeCO2: Fraction of expired CO2; FeO2: Fraction of expired O2; FiO2: 
Fraction of inspired O2.  
5.1.3 Breath-by-breath instruments 
Most modern instruments for indirect calorimetry use so-called “breath-by-breath” 
technology. O2/CO2 concentrations are measured continuously over the respiratory cycle 
close to the patient-ventilator connection, and gas flow is measured by some form of 
spirometry. As there is a variable delay from transit time in the sampling lines and distortion 
of gas concentration waveforms due to fluctuations in airway pressure, the signal has to be 
processed by software algorithms and synchronized to the corresponding flow measurement 
of the breath it was sampled from (Fig. 7). VO2 and VCO2 then calculated for each breath by 
integration of the flow and gas signal using the Haldane transformation. 
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Figure 7. Synchronization of gas sampling and volumetric measurements in breath-by-breath 
indirect calorimetry. The gas waveform is matched to its corresponding flow measurement, then reconstructed to 
compensate for variations in sample flow and rise time of sensors. FeCO2: Fraction of expired CO2. Adapted from Figure 3 in 
Takala, GE Gas Exchange Appliguide, DOC1305573. 
5.1.3.1 Quark RMR 
Quark RMR uses a paramagnetic O2 sensor and infrared CO2 sensor. Gas is sampled from an 
adapter proximal to the ventilator Y-piece or by connecting the sampling line to the heat and 
moisture exchange (HME) filter. Flow is measured at the expiratory port of the ventilator by 
a turbine flowmeter. The instrument uses software compensation to discount the effect of any 
bias flow in the ventilator circuit which must be set manually by the operator. 
5.1.3.2 CCM Express 
CCM Express is a breath-by-breath instrument for indirect calorimetry. Both flow and gas 
concentration signals are transduced from an adapter attached to the patient’s artificial 
airway. Gas flow is measured by a Pitot-tube pneumotachograph. O2 and CO2 concentrations 
are measured by a galvanic fuel cell and infrared sensor respectively. 
5.1.3.3 E-sCOVX 
E-sCOVX also measures gas exchange on a breath-by-breath basis. The instrument is 
connected to the ventilator circuit between the HME filter and Y-piece of the ventilator 
tubing. The adapter includes gas sampling ports and a pneumotachograph which measures 
flow from the pressure drop across a turbulent flow resistor. It contains a paramagnetic O2 
sensor and an infrared CO2 sensor. 
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5.1.4 Calibration 
In measurement technology, accuracy represents the conformity of a measured quantity to the 
actual (true) value. Precision is the ability of an instrument to reproduce that quantity at an 
identical input. As sensors frequently have non-linear properties and may experience decay 
over time, maintaining accuracy and precision requires frequent calibration. The output of a 
sensor is tested over a range of clinically relevant inputs, and sensitivity/zero drift detected 
can be compensated in signal processing 177. 
The instruments used in study I and II were calibrated according to the manufacturer’s 
recommendations. Two-point gas calibration was performed in all devices before each study 
period. Flow calibration is not required for E-sCOVX. The Quark RMR and CCM Express 
flowmeters were calibrated daily with a 3-liter syringe. Prior to both studies the flow 
generator of the respective Deltatrac module used was calibrated by ethanol burning. For 
study II, a full factory calibration of Deltatrac II was performed by engineers at GE 
Healthcare in Helsinki, Finland. 
5.1.5 Data collection from metabolic monitors      
In study I, average values of REE, VO2, VCO2 and RQ were recorded from the display of 
each device at the end of the study period. For CCM Express and Quark RMR, ≥10 minutes 
with a variability of <10% in REE was required. For Deltatrac this was assessed by visual 
inspection of the long trend as the monitor does not provide an index of variability. Deltatrac 
measurements were conducted for ≥20 minutes. 
In study II, digital storage of raw data from all devices was possible. VO2 and VCO2 was 
calculated from data collected during the 20-minute study period. Measurement artifacts from 
coughing or asynchronous breaths were excluded according to pre-defined criteria available 
in the methods section of the published paper. 
5.2 TRACER METHODOLOGY 
5.2.1 Theoretical background 
A “tracer” is a molecule that is functionally indistinguishable from its most abundant 
naturally occurring counterpart (“tracee”) but has structural properties which allows its 
differentiation from the tracee (Fig. 8) 178. Tracers are created by labeling a molecule with 
one or more atoms containing a different number of neutrons in the nucleus than the most 
abundant naturally occurring form, or isotope. Isotopes can be stable or in a state of decay, 
i.e. radioactive. Tracers can be administered to study their metabolic fate in the human body, 
for example their incorporation into macromolecules or metabolites. Another common use of 
tracers in metabolic research is to measure the dilution of tracer by the tracee in the 
bloodstream. From this data the mass transfer (=flux) of tracee entering and leaving the 
circulation can be modeled.  
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Figure 8. Molecular structure of a tracee (L-phenylalanine) and corresponding tracer (L-2H5-
phenylalanine). Original image from Wikimedia Commons.  
The true distribution of a substance within the human body is difficult to determine, as it is 
inhomogeneous and may be regulated both by active and passive processes. Detecting the 
compound of interest is also limited by practical constraints. For example, sampling is most 
readily performed from the bloodstream. Due to these limitations the kinetics and distribution 
of a substance are commonly approximated by mathematical modelling. Theoretical divisions 
of the body between which transfer of a substance may occur are represented as 
compartments or “pools”, in which the substance is assumed to be uniformly distributed 178.  
With regard to amino acids, the simplest representation of the human body is by considering 
it as two metabolic pools: a free amino acid pool (mostly corresponding to plasma volume) 
and body protein. This is illustrated in Fig. 9. Using this model with a tracer dilution 
technique, the fluxes of specific amino acids between these compartments can be estimated. 
The assumptions required for inference about whole-body protein kinetics are described in 
detail below. As this method does not quantify the size of respective pools, it can be referred 
to as “single pool” or non-compartmental modelling 178. 
 
Figure 9. A single pool model for whole-body amino acid kinetics. AA: Amino acid. Image adapted from 
Wagenmakers 179.  
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Amino acids entering the free amino acid pool (Rate of appearance, Ra) will have three 
possible origins:  
i) enteral/parenteral nutrition 
ii) breakdown of body proteins  
iii) de novo synthesis of amino acids 
Using an essential amino acid as tracer will give an accurate representation of protein 
breakdown as there is no contribution of tracee synthesis to Ra. The most common amino 
acid tracers in use are L-1-13C-leucine and L-2H5-phenylalanine 
179. Amino acids leaving the 
circulation (Rate of disappearance, Rd) have five fates:  
i) intracellular accumulation 
ii) incorporation into body proteins  
iii) conversion by modification of functional groups 
iv) elimination by oxidation and nitrogen excretion 
v) loss from the central compartment via bodily fluids 
When a tracer is infused into the central compartment its rate of removal will be proportional 
to the tracer/tracee ratio, as uptake does not discriminate between tracer and tracee. 
Eventually the tracer/tracee ratio will plateau at “isotopic equilibrium”. At this point the 
enrichment of tracer (% tracer/(tracer + tracee)) is constant and Ra will be proportional to the 
tracer infusion rate. This is illustrated in Fig. 10. Expressed in its simplest form, Ra can be 
calculated as 178: 
𝑅𝑎 =  
𝐼𝑛𝑓𝑢𝑠𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑡𝑟𝑎𝑐𝑒𝑟
𝑇𝑟𝑎𝑐𝑒𝑟 𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
 
Although the single-pool model described here is used to quantify several metabolic fluxes of 
amino acids on a whole-body level, Ra is the only value that is truly measured.  
 
Figure 10. Schematic illustration of isotopic equilibrium in plasma (single pool model) during a 
constant tracer infusion. A) As uptake (Rd) does not discriminate between tracer and tracee, more tracer will be 
retained over time until isotopic steady state is achieved. B) Tracer/tracee ratio as a function of time. Sampling at timepoints 1-3 
from panel A are marked on the x-axis. Phe: Phenylalanine; Ra: Rate of appearance; Rd: Rate of disappearance. Adapted from 
Fig. 3.2 in Wolfe and Chinkes, “Isotope Tracers in Metabolic Research”. 
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5.2.2 Modeling whole-body protein kinetics using a L-ring-2H5-phenylalanine 
tracer 
Studies III-IV model whole-body protein kinetics using a non-compartmental stable isotope 
tracer dilution method with L-ring-2H5-phenylalanine (Phe). The calculations of amino acid 
fluxes, required assumptions and limitations of this model are discussed below. These are 
covered more extensively in the literature 178, 180, 181. For a stable isotope tracer, 
𝑅𝑎 = 𝑖 ∗ (
𝐸𝑖
𝐸𝐴
) − 𝑖 
Where i: infusion rate of tracer; Ei: enrichment of infusate; EA: arterial enrichment of tracer. 
As the amount of stable isotope tracer required for a kinetic study will have a significant 
impact on Ra, the second term in this equation corrects for the infusion rate of tracer. Under 
conditions of enteral and/or parenteral nutrition provided at a constant rate:        
𝑃ℎ𝑒 𝑓𝑟𝑜𝑚 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑏𝑟𝑒𝑎𝑘𝑑𝑜𝑤𝑛 (𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑅𝑎) = 𝑅𝑎 𝑃ℎ𝑒 − 𝑑𝑖𝑒𝑡𝑎𝑟𝑦 𝑃ℎ𝑒 
The contribution of parenteral amino acids to dietary Phe is straightforward as they are 
administered directly into the bloodstream. Enteral amino acids are subject to variable first-
pass uptake by the splanchnic organs 149, 150, 182. The splanchnic extraction fraction can be 
quantified by infusing an enteral tracer. In studies III and IV 1-13C-phenylalanine was used 
for this purpose: 
𝑆𝑝𝑙𝑎𝑛𝑐ℎ𝑛𝑖𝑐 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 = 1 −
𝐸𝐴 [13𝐶]𝑃ℎ𝑒
𝑖[13𝐶]𝑃ℎ𝑒
𝐸𝐴 [2𝐻5]𝑃ℎ𝑒
𝑖[2𝐻5]𝑃ℎ𝑒
 
Assumption 1: Endogenous Ra of phenylalanine reflects the relative phenylalanine content in 
proteins, i.e. whole-body protein breakdown. Data from healthy volunteers with multiple 
concurrent tracers and determinations of nitrogen balance supports this 183.  
Assumption 2: Rd equals Ra at physiological steady state. While this is true, steady state 
conditions in protein turnover are impossible to verify as changes in Rd will not affect tracer 
dilution (relative rate of tracer and tracee removal is identical). All kinetic parameters derived 
from Rd are therefore associated with a higher degree of uncertainty than Ra.  
𝑅𝑑 = 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑠𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑠 + 𝑎𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑 𝑜𝑥𝑖𝑑𝑎𝑡𝑖𝑜𝑛 
Assumption 3: The rate of amino acids lost to sweat or urine is negligible compared to other 
metabolic fluxes. This was not assessed within the context of studies III-IV. In study IV Rd 
was adjusted for amino acids lost to dialysis effluent.  
The first and rate-limiting step of phenylalanine oxidation is the irreversible conversion to 
tyrosine by hydroxylation. This reaction mainly takes place in the liver 184. The conversion of 
phenylalanine to tyrosine (Qpt) can be estimated by simultaneously measuring the enrichment 
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of ring-2H4-tyrosine (the metabolite of ring-
2H5-phenylalanine) and whole-body Ra of 
tyrosine from an infusion of 2H2-tyrosine: 
𝑄𝑝𝑡 = 𝑅𝑎[2𝐻2]𝑇𝑦𝑟 ∗
𝐸𝐴 [2𝐻4]𝑇𝑦𝑟
𝐸𝐴 [2𝐻5]𝑃ℎ𝑒
∗
𝑅𝑎𝑃ℎ𝑒
𝑖𝑃ℎ𝑒 +  𝑅𝑎𝑃ℎ𝑒
 
Assumption 4: The rate of phenylalanine hydroxylation is proportional to its oxidation rate. 
As tyrosine may have other metabolic fates this will lead to an underestimation of protein 
oxidation. Phe oxidation estimated from Qpt was in agreement with oxidation determined by 
the incorporation of 1-13C-Phe into exhaled CO2 (a more direct measurement of oxidative 
metabolism) in healthy volunteers 185. Absolute values of protein oxidation are variable 
depending on the tracer used 151.     
Assumption 5: The proportion of RdPhe not converted to tyrosine is used for protein synthesis. 
The model does not consider the possible of intracellular accumulation of free phenylalanine, 
which would result in an overestimation of protein synthesis.   
Whole-body balance of phenylalanine, and by inference protein balance, is calculated as: 
𝐵𝑎𝑙𝑎𝑛𝑐𝑒𝑃ℎ𝑒 = 𝑆𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑠 (𝑅𝑑 − 𝑄𝑝𝑡) − 𝐵𝑟𝑒𝑎𝑘𝑑𝑜𝑤𝑛 (𝑅𝑎 − 𝑑𝑖𝑒𝑡𝑎𝑟𝑦 𝑃ℎ𝑒) 
As balance is calculated from two fluxes that are an order of magnitude larger than the result, 
small errors in the determination of synthesis or breakdown will yield larger errors in net 
balance.  
5.2.3 Determining tracer enrichment 
Enrichment can be described in terms of tracer to tracee ratio (TTR, a dimensionless 
number), atom percentage excess (APE, %) or molar percentage excess (MPE, %) 186. APE 
represents the excess of isotopically labeled atoms in a sample and MPE the excess of labeled 
molecules. APE and MPE are derived from TTR as 
𝑀𝑃𝐸 =  
𝑇𝑇𝑅
(1 + 𝑇𝑇𝑅)
∗ 100 
Detection of the relative quantities of tracer and tracee in a sample requires highly accurate 
measurements of molecular mass. This is performed by gas chromatography-mass 
spectrometry (GCMS). An extensive description of this technique can be found in the 
reference which this section is based on 178.  
The principle of mass spectrometry is to measure the molecular weight of a sample by 
fragmenting it into component ions. Blood samples are initially centrifuged to plasma and 
frozen at -80°C waiting analysis. Amino acids in a sample are treated with chemical 
derivatization agent (MTBSTFA, or N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide) 
to decrease polarity and make the compounds more volatile. The sample is then injected into 
the gas chromatograph, vaporized, and passed through a solid phase column by a carrier gas. 
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This process separates different compounds in the sample and allows them to pass into the 
mass spectrometer in order, thereby facilitating detection. 
Compounds introduced into the MS device are fragmented to ions with a specific 
mass/charge ratio (m/z), and passed through a magnetic field towards a detector plate. The 
dispersion pattern of the sample will depend on the m/z of a compound, providing a 
“fingerprint” for a particular molecule.  
Tracer samples in studies III and IV were analyzed by an Agilent N5973 GCMS (Agilent, 
Kista, Sweden), m/z 336 and 341 for phenylalanine and 466, 468 and 470 for tyrosine. 
5.2.4 Other analytical methods 
Plasma amino acid profiles were analyzed using high-performance liquid chromatography 
(HPLC) 187 Alliance HPLC System (Waters Corporation, Milford, MA, USA). Serum urea 
was analyzed using Urea kit on Indiko analyzer (Thermo Fisher Scientific, Waltham, MA, 
USA). 
5.3 STATISTICAL ANALYSIS 
5.3.1 Inferential statistics 
Statistical significance tests are used to determine the probability (p-value) of an observation, 
given that the test hypothesis and all assumptions underlying the test are valid 188. It is 
common practice in medical statistics to select an upper limit of “significance” for a p-value a 
priori (<0.05). Findings with significant p-values are often considered as not attributable to 
chance 189. This is an inherently flawed interpretation and the utility in standard reporting of 
p-values is contested 190. Furthermore, statistical tests require assumptions about the 
population from which a sample is derived, and the conditionality of these assumptions (such 
as the underlying probability distribution) are difficult to ascertain in smaller samples. As all 
studies included in this thesis (particularly III and IV) contain small groups of patients, 
reported results from significance testing should be interpreted with caution. This is of even 
greater importance for secondary outcomes due to multiple comparisons. The statistical tests 
used in studies I-IV are listed in Table 4. 
In study I, no a priori sample size calculation was performed.  
In study II, a target of N=50 observations was chosen to determine 95% limits of agreement 
within ±2 sample standard deviations (SD) from Student’s t-distribution.  
In study III, a target of N=10 observations was chosen based on previous data149 to detect a 
change from negative to net zero protein balance with α = 0.05 and ß = 0.2.   
In study IV, a target of N=12 observations was chosen based on previous data151 to detect a 
change from negative to net zero protein balance with α = 0.05 and ß = 0.2, assuming N=2 
protocol violations.  
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All descriptive data and results normalized to body weight (BW) are adjusted using the same 
formula as applied in local clinical nutrition practice:  
𝐵𝑊𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑(𝑘𝑔) = 𝐵𝑊𝑖𝑑𝑒𝑎𝑙 (ℎ𝑒𝑖𝑔ℎ𝑡 (𝑐𝑚) − 100) + (𝐵𝑊𝑎𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛 − 𝐵𝑊𝑖𝑑𝑒𝑎𝑙) ∗ 0.33 
If admission BW was less than ideal BW, admission BW is used instead of adjusted BW.  
In the published paper to study III, results from protein kinetics were normalized to admission 
BW. To allow better comparisons of results with study IV this data is presented in the thesis 
as normalized to adjusted BW. One-way ANOVA of adjusted values were calculated 
applying a Greenhouse-Geisser correction (equal variances not assumed). In addition, 
administered doses of amino acids are expressed as protein substrate, using a factor of 0.83 to 
correct for hydration of free amino acids 191.   
Statistical tests and calculations in studies I and II were performed in Excel 2010 and 2013 
(Microsoft corporation, Redmond, WA, USA) respectively. Tests in study III were performed 
in SPSS Statistics version 24 (IBM, Armonk, NY, USA) and Prism version 7 (GraphPad 
Software Inc, La Jolla, CA, USA). Tests in study IV were performed in Prism version 8.3 
(GraphPad Software Inc, San Diego, USA).    
Table 4. Statistical methods in studies I-IV. 
 Descriptive statistics Inferential statistics Other methods 
Study I Median/mean (range), mean ± 
standard deviation 
Two-tailed Student’s t-test for 
paired samples 
Bland-Altman plots. Acceptable 
limits of agreement not defined a 
priori. 
Study II Mean ± standard deviation Significance testing not presented 
in paper.  
Bland-Altman plots. Acceptable 
limits of agreement not defined a 
priori. 
Study III Median (range) One-way analysis of variance 
(ANOVA) for comparison of 
multiple paired samples. Two-
tailed Student’s t-test or Wilcoxon 
signed-rank test for paired 
samples as appropriate.  
Sphericity of multiple paired 
samples assessed by Mauchly’s 
test of sphericity. Greenhouse-
Geisser correction applied as 
appropriate. Bonferroni correction 
applied for post-hoc testing.  
Study IV Mean (range) Two-tailed Student’s t-test for 
paired samples 
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5.3.2 Bland-Altman analysis 
Bland-Altman plots were used to assess agreement between methods in studies I and II 192. 
The 95% limits of agreement were calculated as  
?̅? ± (𝑡𝛼 0.05,𝑑.𝑓.𝑛−1) ∗ 𝑠𝑑 
using Student’s t-distribution, where 𝑠𝑑: sample standard deviation of difference between 
methods and ?̅?: mean difference between methods. Percentage error (PE), an expression of 
the range of discrepancy between paired measurements in relation to the mean of the 
measured quantity, is given as 
𝑃𝐸 = (𝑡𝛼 0.05,𝑑.𝑓.𝑛−1) ∗ 𝑠𝑑/?̅? 
where ?̅?: mean of both methods.  
The original description of the Bland-Altman plot only considered independent observations, 
and alternative approaches using both independent and repeated measurements have been 
described 193, 194. As multiple observations of individual patients in studies I and II were only 
performed on separate days we have considered them as independent for the purposes of 
assessing agreement between methods. 
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6 MAIN RESULTS AND DISCUSSION 
This section summarizes the main findings of studies I-IV. Full results are reported in the 
individual papers and manuscript. 
6.1 STUDIES I AND II 
6.1.1 Results 
In study I, we performed 48 sequential measurements with all three instruments in 24 
patients. Recruitment was prematurely terminated due to a lack of calibration gas for CCM 
Express. Mean values of energy expenditure and gas exchange measurements are reported in 
Table 5. There was no statistically significant difference in mean REE between Quark RMR 
and Deltatrac. CCM Express measured higher REE values in all cases, corresponding to a 
mean REE 64% higher than Deltatrac. Mean RQ was also different between all three 
instruments, with Deltatrac registering the lowest RQ values on average. Graphical 
comparisons with Bland-Altman plots between Deltatrac and the evaluated devices are 
presented in Fig. 11. Bias and 95% limits of agreement are listed in Table 6. Percentage error 
of REE (~2*SD of difference/mean of both methods) was ±31% between Deltatrac and CCM 
Express, and ±22% between Deltatrac and Quark RMR.   
In study II, 48 simultaneous measurements in 22 patients with Deltatrac II and both evaluated 
instruments were included for analysis. Both Quark RMR and E-sCOVX measured higher 
mean VO2 and VCO2 than Deltatrac II, corresponding to a mean difference in REE of 10% 
(Table 7). The agreement between instruments is illustrated with Bland-Altman plots in Fig. 
12. Bias, 95% limits of agreement and percentage errors are listed in Table 8. 
To compare indirect calorimetry with predictive equations, an exploratory analysis of 
individual patients from studies I and II was performed post-hoc. Mean measured energy 
expenditure by Deltatrac was higher (1806 kcal/day) compared to estimations of energy 
expenditure used in local clinical practice (1486 kcal/day) or the Harris-Benedict equation10 
(1613 kcal/day). There was a weak correlation between measured and estimated EE (Fig. 13), 
with measured EE ranging between 16-35 kcal/kg/day. 
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Table 5. Mean gas exchange parameters of instruments in study I. 
 REE VO2 VCO2 RQ 
Deltatrac 1749 ±57 261 ±8 193 ±6 0.74 ±0.01 
Quark RMR 1788 ±72 259 ±11 211 ±9 0.81 ±0.01 
CCM Express 2876 ±96 408 ±14 352 ±11 0.87 ±0.01 
REE: Resting energy expenditure (kcal/day); RQ: Respiratory quotient; VO2: Oxygen consumption (ml/min); VCO2: Carbon 
dioxide production (ml/min).  
All values presented as mean ± standard error of the mean.   
 
Table 6. Comparisons of mean difference in gas exchange parameters between instruments in 
study I. 
 Bias* 95% limits of agreement** Percentage error† 
Quark-Deltatrac VO2 -2 (-11 - +6) -60 - +56 ±22% 
Quark-Deltatrac VCO2 +19 (+11 - +26) -35 - +70 ±27% 
Quark-Deltatrac REE +39 (-17 - +96) -350 - +429 ±22% 
CCM Express-Deltatrac VO2 +147 (+131 - +162) +40 - +254 ±32% 
CCM Express-Deltatrac VCO2 +159 (+147 - +172) +73 - +245 ±32% 
CCM Express-Deltatrac REE +1127 (+1022 - +1231) +404 - +1849 ±31% 
LoA: Limits of agreement; REE: Resting energy expenditure (kcal/day); VO2: Oxygen consumption (ml/min); VCO2: Carbon 
dioxide production (ml/min). 
*Mean difference (95% confidence interval). 
** 95% limits of agreement = bias ± 2 standard deviations of differences between methods.  
† Percentage error = ±2 standard deviations of difference between methods/mean of both methods. 
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Figure 11. Bland-Altman plots of VO2, VCO2 and REE comparing Quark RMR-Deltatrac and 
CCM Express-Deltatrac in study I. REE: Resting energy expenditure (kcal/day); VO2: Oxygen consumption (ml/min); 
VCO2: Carbon dioxide production (ml/min). Solid line: mean difference; Dashed lines: 95% limits of agreement of difference. 
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Table 7. Mean gas exchange parameters of instruments in study II. 
 REE VO2 VCO2 RQ 
Deltatrac* 1986 ±56/2041 ±59 289 ±8/296 ±9 218 ±6/226 ±6 0.76 ±0.01/0.77 ±0.01 
Quark RMR 2191 ±65 314 ±10 258 ±7 0.83 ±0.01 
E-sCOVX 2255 ±63 323 ±9 263 ±7 0.82 ±0.01 
REE: Resting energy expenditure (kcal/day); RQ: Respiratory quotient; VO2: Oxygen consumption (ml/min); VCO2: 
Carbon dioxide production (ml/min).  
All values presented as mean ± standard error of the mean.  
*Mean values from Quark/E-sCOVX comparison.  
 
Table 8. Comparisons of mean difference in gas exchange parameters between 
instruments in study II. 
 Bias*  95% LoA** Percentage error† 
Quark-Deltatrac VO2 +25 (+14 - +36) -49 - +98 ±24% 
Quark-Deltatrac VCO2 +40 (+33 - +47) -11 - +90 ±21% 
Quark-Deltatrac REE +205 (+138 - +272) -261 - +671 ±22% 
E-sCOVX-Deltatrac VO2 +27 (+17 - +38) -44 - +99 ±23% 
E-sCOVX-Deltatrac VCO2 +37 (+31 - +44) -8 - +83 ±19% 
E-sCOVX-Deltatrac REE +215 (+148 - +281) -246 - +676 ±21% 
LoA: Limits of agreement; REE: Resting energy expenditure (kcal/day); VO2: Oxygen consumption (ml/min); VCO2: 
Carbon dioxide production (ml/min). 
*Mean difference (95% confidence interval).  
**95% limits of agreement = bias ± 2 standard deviations of differences between methods.  
†Percentage error = ±2 standard deviations of difference between methods/mean of both methods. 
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Figure 12. Bland-Altman plots of VO2, VCO2 and REE comparing Quark RMR-Deltatrac II and E-
sCOVX-Deltatrac II in study II. REE: Resting energy expenditure (kcal/day); VO2: Oxygen consumption (ml/min); 
VCO2: Carbon dioxide production (ml/min). Solid line: mean difference; Dashed lines: 95% limits of agreement of difference.  
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Figure 13. Simple linear correlation between measured REE (Deltatrac) and weight-based 
estimations of REE (20 kcal/kg ABW/day and the Harris-Benedict equation) from individual 
patients (N=46) in studies I and II. Mean value of both Deltatrac measurements used from study II. ABW: Adjusted 
body weight; HBE: Harris-Benedict equation; REE: Resting energy expenditure; r: Pearson product-moment correlation 
coefficient. Solid line: line of identity. 
 
6.1.2 Discussion 
Our results demonstrate a variable agreement between indirect calorimetry with mixing 
chamber technology (Deltatrac I/II) and breath-by-breath instruments. One device (CCM 
Express) overestimated REE to a degree that is not acceptable for clinical purposes. The other 
two instruments had similar performance characteristics for gas exchange measurements 
compared to Deltatrac. Measured energy expenditure was highly variable and did not 
correlate well with estimations from anthropometric properties.  
The implications of these findings for the use of new devices in an intensive care setting 
depend on two central questions: 
i) Is the Deltatrac monitor accurately considered a “gold standard” for gas exchange 
measurements in mechanically ventilated ICU patients? 
ii) What level of agreement is considered acceptable in relation to the reference method?    
From a diagnostic perspective, a gold standard is the method which will yield a result closest 
to the true value of the property investigated. An in vitro validation of Deltatrac by Takala 
using gas injectors and ethanol burning in a model of mechanical ventilation, demonstrated a 
mean error in VO2, VCO2 and RQ of 2-4% over a clinically relevant range of FiO2 and 
airway pressures 21. The authors also performed a comparison of VO2 in mechanically 
ventilated patients using the Fick principle, but note that in vivo validation is limited by the 
absence of an accurate reference method. Tissot and co-workers compared VO2/VCO2 
measurements by Deltatrac in mechanically ventilated patients in 8-hour measurements with 
an experimental setup combining a mass spectrometer and pneumotach flowmeter 22. Limits 
of agreement are not explicitly stated, but from visual inspection appear to be smaller (around 
±17 ml/min for VO2) than the variability observed in the studies of this thesis.  
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Despite this superior agreement it is not self-evident that the experimental system used for in 
vivo validation represents a gold standard comparator. Although mass spectrometry provides 
highly accurate measurements of gas concentrations, the gas sensors used in commercial 
instruments also have a high degree of accuracy and is likely not a major source of variable 
error. The validation setup in the study by Tissot uses a mixing chamber for collection of 
expired gas 195. This similarity in design to Deltatrac, and prolonged measurement periods, 
may explain the high level of agreement observed. The use of mixing chamber technology for 
gas exchange measurements circumvents the technical challenge of accurate synchronization 
of breath-by-breath measurements, which can be especially difficult in spontaneously 
breathing patients. This theoretical advantage in design and the high degree of accuracy 
observed in in vivo validations are appealing arguments when considering the status of 
Deltatrac as a reference method in clinical practice. It must also be taken into consideration 
that the Deltatrac is an aging piece of equipment. Both units in our unit had been in prior use 
for over 20 years. Although the instruments were serviced and passed a full calibration prior 
to both studies, deterioration of function over time cannot be ruled out. In particular, the 
unexplained RQ values outside of normal physiologic range are a cause for concern. 
If we accept Deltatrac as a gold standard method, this begets the question to what degree 
diverging measurements in other devices are acceptable for clinical purposes. A proportional 
bias over the full range of measurements could be compensated by a calibration factor. 
Regarding variability, the original article by Bland and Altman proposes that the differences 
encompassed by the 95% limits of agreement (~ ±2SD) should be within a clinically 
acceptable range 192. Long-term underfeeding or overfeeding have potentially negative 
consequences and significant deviations from the true value of EE are undesirable for clinical 
decision-making. As there is insufficient evidence to determine a dose-response relationship 
for benefit or harm from energy delivery during critical illness, an acceptable degree of 
variability is difficult to define a priori.  
The criterion proposed by Critchley is commonly applied for method comparisons of cardiac 
output measurements 196. It is based on the assumption that any method measuring a constant 
true value will yield variable results by random error. The magnitude of this error can be 
described by its normalized probability distribution, or coefficient of variation (CV = 
SD/mean). The combined CV of two methods, directly proportional to the standard deviation 
of the differences between methods, is then calculated as the square root of the summed 
variance of each device (Fig. 14).  
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Figure 14. An illustration of a Pythagorean approach to calculating the combined precision of 
two measurement techniques. CV: Coefficient of variation, Var: Variance; σ: Standard deviation. Adapted from 
Critchley & Critchley 1999 196.    
Assuming a precision (≈ 2*CV) of ±20% for the reference method, a percentage error of no 
more than ±28.3% is acceptable if the alternate method is to measure the true value with 
equal or greater precision. A review by Cecconi elaborates on this idea by stating that the 
precision of the gold standard may in fact be lower than ±20% 197. Accordingly, they 
conclude that the a priori acceptable percentage error should be determined by first measuring 
the CV of the reference method within the context of the same study.  
One limitation of this approach when applied to indirect calorimetry is that the output 
variables (VO2 and VCO2) may behave in a non-stochastic fashion depending on the input 
conditions (respiration patterns, airway pressures, humidity, etc.), resulting in variable non-
random, systematic error (=bias) for individual measurements. Due to the black box design of 
modern monitors the contribution of such factors to observed variability could not be 
determined within the context of these studies. Post-hoc analysis of raw data from E-sCOVX 
by engineers at GE Healthcare indicated that the absence of bias flow may interfere with 
synchronization of gas and flow measurements and offset certain results. Interestingly, Stapel 
and colleagues performed a similar study comparing E-sCOVX and Deltatrac using 
ventilators with a bias flow setting 28. Although concluding that the mean difference (12% of 
REE) was unacceptable for clinical practice, the 95% limits of agreement were narrower 
(percentage error ±14%) than those found in study II.  
The 95% limits of agreement of REE for Quark and E-sCOVX compared to Deltatrac 
expressed as percentage error were ±22%. This is lower than the upper boundary proposed by 
Critchley and substantially less than that of minimally invasive cardiac output monitors 
commonly used in critical care 198. Our results are consistent with other comparisons of 
Deltatrac and modern instruments for indirect calorimetry reported in the literature 25-28. Of 
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note, results from a recently published evaluation of a new calorimeter calls the 
reproducibility of estimated agreement into question 199. In a multicenter study of the Q-NRG 
device, the investigators report comparisons with Deltatrac from three different study sites. 
Bias varied between -307 to +23 kcal, and 95% limits of agreement from ±158 to 328 kcal. 
Several factors may contribute to observed differences: local ventilation practices, attention to 
detail in minimizing potential sources of measurement error, function and maintenance of the 
reference device, and random effects from patient sampling. Regardless of the reasons for 
these discrepancies, the observed variations lower the probability that any new device will 
consistently outperform those currently on the market with regard to agreement with 
Deltatrac. It also raises the question for how long a decommissioned instrument can be 
considered a gold standard. For future developments in indirect calorimetry, it is essential that 
manufacturers evaluate their products in vivo under simulated conditions close to those in 
clinical practice. It is also desirable that new devices are systematically compared to other 
commercially available instruments in the relevant clinical setting. 
The mean observed difference between Quark RMR, E-sCOVX and Deltatrac corresponds to 
a 10% higher REE from breath-by-breath instruments. In study I we found no difference in 
mean REE between Quark and Deltatrac. However, this result is likely subject to systematic 
error from bias flow compensation. The presence of ventilator bias flow was manually 
determined by visual inspection of the flow profile according to the manufacturer’s 
recommendation. During the conduct of study II we were informed that the ventilators in our 
unit (Dräger Evita XL) did not have a bias flow setting in adult mode, and bias flow 
compensation was retroactively set to zero. The latter result therefore represents a more 
accurate estimation of the mean difference between Quark and Deltatrac.  
One monitor (CCM Express) gave exceptionally high values of VO2, VCO2 and resulting 
REE. The mean difference in VO2 and VCO2 between this device and Deltatrac corresponds 
to 64% higher REE values. Limits of agreement were also wider (PE = ±32%) than 
comparisons for other instruments. Another validation study using CCM Express may 
provide insight into a potential cause for this difference. Graf and colleagues evaluated CCM 
Express against Deltatrac in critically ill patients, using a protocol similar to that in study II 
27. They found a lower bias (+273 kcal/day) but similar 95% limits of agreement (±532 
kcal/day). In this setup the CCM flowmeter was attached distal to the HME filter, whereas in 
study I it was connected directly to the endotracheal or tracheostomy tube according to 
instructions from the manufacturer. This could affect synchronization of gas concentrations 
and flow from the difference in dead space volume proximal to the point of measurement. It 
may also lead to different conditions in heat and humidity with implications for the output 
accuracy of gas analyzers. From an engineering perspective, it is crucial that manufacturers 
take these issues into consideration when designing equipment for use in intensive care. 
There are several limitations to study I which we attempted to address in study II. The main 
disadvantage was the long period required to perform all measurements in sequence. This 
increases the risk of changing metabolic rate and non-steady state conditions in the volatile 
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carbon pool between measurements. Second, no consideration was taken to differences in 
artifact suppression between devices. Third, the protocol necessitates several disconnections 
of the ventilator circuit between measurements. The introduction of ambient air into the 
mixing chamber will affect measurements by Deltatrac until steady state conditions are 
achieved. In study II, a mandatory run-in period after connection was introduced to minimize 
this source of error. Fourth, both studies allowed for repeated measurements on different 
days. For the purposes of comparative statistics and Bland-Altman analyses these data points 
were treated as independent observations, as there is potential for considerable day-to-day 
variability in the physiologic state of individual ICU patients. Hypothetically, a specific set of 
patient-ventilator interactions in an individual patient could generate outlier results or 
stronger agreement in a certain device. If multiple measurements are performed under similar 
conditions this may be sufficient to offset the sample mean. To account for this a minimum of 
20 measurements in unique patients was mandated. Post-hoc analysis of the first 
measurements performed in subjects shows a similar mean REE for each instrument as the 
complete data set in both studies. 
6.2 STUDIES III AND IV 
The common primary aim of studies III and IV was to evaluate the effects of macronutrient 
delivery on whole-body protein balance. Due to the similarities in methodology the studies 
are reported together below.  
6.2.1 Results study III 
12 patients were recruited during the study period. 8 patients completed the full protocol. 3 
patients had outcome data for baseline and 3 h, and one patient for baseline and 24 h. 
Median length of stay in ICU on study day 1 was 6 (range 3 – 18) days. Energy and protein 
delivery for individual patients is described in Table 9. 
During the 24 h amino acid infusion there was a sustained improvement in protein balance 
over time, from net negative to positive. Post-hoc testing did not indicate any change in 
balance between 3 h and 24 h (p = 1.00). Changes in synthesis, breakdown or oxidation rate 
did not reach statistical significance. Mean values of protein kinetic parameters are listed in 
Table 10. Protein kinetics for individual patients are illustrated in Fig. 15 and mean balance in 
Fig. 16. 
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Table 9. Nutritional therapy in patients with complete data for the primary outcome in study III. 
 EN formula 
Parenteral 
nutrition 
Energy 
(baseline)* 
Energy (AA 
infusion)* 
Protein 
(baseline)** 
Protein (AA 
infusion)** 
Patient 1 Fresubin 2 kcal HP  24.8 28.7 1.24 2.04 
Patient 2 Fresubin 2 kcal HP  17.6 21.5 0.88 1.68 
Patient 3 Fresubin 2 kcal HP Glucose 5% 24.6 28.4 0.92 1.72 
Patient 4 - Olimel 1600 18.0 21.9 0.96 1.76 
Patient 6 Nutrison 1 kcal - 22.7 26.6 0.91 1.71 
Patient 10 Fresubin HP Energy Glucose 5% 31.5 35.4 1.43 2.23 
Patient 11 - 
Olimel 1070, 
Glucose 5% 
14.6 18.4 0.59 1.39 
Patient 12 Fresubin HP Energy  22.2 26.1 1.11 1.91 
Mean   22.0 25.9 1.00 1.81 
AA: Amino acids; EN: Enteral nutrition; LoS: Length of stay (days).   
* Kcal/kg/day.  
** Grams/kg/day. Amino acids converted to protein substrate with hydration factor of 0.83.  
 
Table 10. Phenylalanine kinetics, plasma free amino acids and serum urea in study III. 
 Baseline 3h AA infusion 24h AA infusion P-value** 
Net balance* -1.6 (-8.3 – 5.0) 6.8 (-1.7 – 15.3) 8.4 (3.8 – 13.1) 0.0044 
Synthesis* 67.9 (61.3 – 74.4) 82.0 (59.5 – 104.5) 71.7 (60.6 – 82.9) 0.28 
Breakdown* 69.5 (58.0 – 81.0) 75.2 (49.0 – 101.4) 63.3 (52.2 – 74.4) 0.42 
Oxidation* 15.2 (11.7 – 18.8) 19.4 (12.8 – 26.0) 14.2 (11.3 – 17.0) 0.15 
Plasma AA (µmol/L) 3064 (2533 – 3596) 3229 (2982 – 3476) 3599 (3186 – 4012) 0.059 
Serum urea (mmol/L) 13.8 (6.8 – 20.8) 13.8 (7.0 – 20.6) 15.4 (8.3 – 22.4) 0.053 
AA: Amino acids.  
* µmol Phenylalanine/kg/h, mean (95% confidence interval).  
** One-way ANOVA for repeated measurements, Greenhouse-Geisser correction applied. 
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Figure 15. Whole-body phenylalanine balance, synthesis, breakdown and oxidation rates over 
time in study III. Phe: Phenylalanine. Black lines: individual patients; Red line: mean.  
 
 
Figure 16. Mean whole-body phenylalanine balance in study III. AA: amino acids. Black bars: net balance; 
Red bars: breakdown; White bars: synthesis; Whiskers: Upper limit of 95% confidence interval. 
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6.2.2 Results study IV 
Of 12 patients recruited during the study period, 6 were excluded due to protocol violations 
or clinical circumstances. The nutritional and metabolic characteristics of individual patients 
are described in Table 11. 
 
Table 11. Individual patient nutritional and metabolic characteristics in study IV. 
 
LoS study 
day 1 
CRRT EE* 
baseline 
EE*   
50% EN 
EE*    
100% EN 
Kcal 
50% 
Kcal 
100% 
Protein** 
50% 
Protein** 
100% 
Patient 1 5 Day 1&2 27.8 22.4 Missing value 14.0 26.4 0.80 1.60 
Patient 2 21 Day 1&2 29.3 29.3 33.2 15.6 29.3 0.89 1.78 
Patient 5 28 No 40.8 31.3 37.8 19.9 39.9 1.00 1.99 
Patient 8 30 Day 1 44.6 46.8 Missing value 24.9 44.5 1.38 2.77 
Patient 10 9 No 26.3 30.5 34.7 12.8 25.5 0.64 1.28 
Patient 11 7 No 29.2 34.5 38.5 17.1 31.2 0.60 1.20 
Mean   33.0   16.3 32.2 0.89 1.77 
CRRT: Continuous renal replacement therapy; EE: Energy expenditure; EN: Enteral nutrition; LoS: Length of ICU stay. 
*Kcal/kg/day 
**g/kg/day 
 
During 100% EN we observed an increase in mean protein balance, from -6.1 to 2.9 µmol 
Phe/kg/h (p = 0.044). There were no significant changes in other kinetic parameters. Mean 
plasma amino acid concentrations were also higher during full-dose EN, 2632 vs 2173 
µmol/L (p = 0.011). Protein kinetics for individual patients during 50% and 100% EN are 
illustrated in Fig. 17. Mean balance is illustrated in Fig. 18.  
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Figure 17. Whole-body phenylalanine kinetics during 50 and 100% EN in study IV. EN: Enteral 
nutrition; Phe: Phenylalanine. Black lines: individual patients; Red lines: mean.  
 
 
Figure 18. Mean whole-body phenylalanine balance in study IV. EN: Enteral nutrition. Black bars: net 
balance; Red bars: breakdown; White bars: synthesis; Whiskers: Upper limit of 95% confidence interval. 
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6.2.3 Discussion 
Studies III and IV investigated the effects of two different macronutrient supplementation 
strategies on whole-body protein balance in critically ill patients. In study III we administered 
an infusion of parenteral amino acids in addition to standard nutrition over 24 hours. In study 
IV we provided half- or full-dose EN in relation to energy expenditure for 24 hours in a 
cross-over design. The similar and diverging aspects of these studies discussed in this section 
are listed below:  
1. The importance of protein intake for whole-body protein balance  
2. Is there a clinical benefit to a neutral/positive protein balance? 
3. Is energy delivery an important determinant of whole-body protein balance? 
4. Limitations of studies III and IV 
5. Strengths of studies III and IV 
 
1. The importance of protein intake for whole-body protein balance 
A common feature in both studies is the significant increase in protein delivery. Mean protein 
substrate intake during the high supplementation periods was 1.8 (1.20 – 2.77) g/kg/day. An 
exploratory analysis of all patients at baseline and after the 24 h intervention periods shows a 
significant correlation (R2 = 0.446, p <0.001) between protein intake and net whole-body 
balance (Fig. 19). This dose-response relationship is consistent with previous findings from 
short-term tracer studies by our research group 200. In addition, the observations from studies 
III and IV show that this response is sustained for up to 24 hours, both during enteral feeding 
and parenteral AA supplementation.  
 
Figure 19. Whole-body protein balance in relation to protein intake in studies III and IV. Values 
included from baseline and after the 24 h intervention period with supplementation (Glavamin infusion or 100% enteral nutriton), 
N = 15 patients. Phe: Phenylalanine. Black dots: individual data points study III; Red dots: individual data points study IV; Solid 
black line: simple linear regression; Dashed lines: 95% confidence interval of regression line. 
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Although any form of post-hoc analysis needs to be interpreted with caution, two hypotheses 
may be drawn from linear regression in this data set:  
i) Mean protein intake to achieve a net neutral balance appears to lie somewhere 
between 1-1.5 g/kg/day. This is roughly equivalent to the recommendations in clinical 
guidelines, based on nitrogen balance studies and retrospective observational data 
correlating protein intake to survival 160. 
ii) There is no obvious ceiling effect between protein delivery and net balance. Due to 
the limited number of patients receiving >2 g protein/kg/day, this observation is 
tenuous and would have to be confirmed in studies designed to investigate a dose-
response relationship over a wider range of intakes. Data from small physiological 
investigations in patients with burns, trauma and sepsis indicate that intakes above 
1.4-1.5 g/kg/day have no additional effect on protein synthesis or catabolism 201-203. 
 
2. Is there a clinical benefit to a neutral/positive protein balance?  
To be of utility as a surrogate outcome, any improvement in protein balance from an 
intervention during critical illness needs to  
i) result in the sparing of lean body mass or increased synthesis of proteins relevant to 
survival or functional outcomes, and 
ii) be sustained over time. 
An inherent limitation of the tracer dilution method is that it provides no information about 
the relative contribution of regional protein balance in different tissues towards an observed 
change in whole-body balance. Phenylalanine balance for individual patients in studies III 
and IV spanned between -4.0 and 16.8 µmol/kg/h during high protein delivery. Assuming a 
phenylalanine content of 4% in muscle protein, this would correspond to a change in 
hydrated lean body mass between -2.0 to 8.3 g/kg/day. It is implausible that any patient 
would gain significant muscle mass during ICU stay. Therefore, the major impact of 
supplementation is likely on tissues with higher baseline rates of protein turnover such as the 
splanchnic organs and immune system. The only study investigating the effects of nutrition 
on regional protein metabolism in muscle during critical illness is by Leverve from 1984 204. 
Their results demonstrate a lower femoral vein output of amino acids during TPN with a high 
protein content. Future tracer investigations in ICU patients should attempt to quantify the 
relative contribution from specific organ pools to the observed difference in whole-body 
protein kinetics. 
The results from studies III and IV indicate that the improved protein balance from increasing 
protein delivery is sustained for up to 24 hours. We cannot rule out that this response would 
be attenuated over time by adaptation to higher intake. This phenomenon has been observed 
when measuring nitrogen balance during critical illness. Larsson found an improved daily 
protein balance with 0.65 g/kg/day compared to 1.3 g/kg/day in 39 patients with trauma and 
burns, but by day 8 there was no difference in cumulative balance 203. The larger and more 
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recent EAT-ICU trial by Allingstrup and co-workers makes a similar observation 119. 203 
ICU patients were randomized to either standard nutrition or isocaloric energy provision and 
1.5 g/kg/day of protein. Calculated balance was more positive in the intervention group on 
day 1, but the 95% confidence intervals of the mean difference spanned zero on day 3 and 
beyond. Also, the increase in protein and energy delivery did not result in functional 
improvement after six months. These findings indicate that critically ill patients with higher 
protein intake may use an increased proportion of amino acids for oxidative metabolism over 
time. We did not observe an increase in amino acid oxidation or serum urea, but this could be 
due to the relatively short observation period and small sample size. The Nephro-Protective 
trial by Doig and colleagues randomized 474 adult ICU patients to standard care or a daily 
supplement of i.v. amino acids similar to the dose in study III 162. They observed a daily 
increase in serum urea over the first seven days in the intervention group (Supplement 2), 
which in the absence of difference in the duration of renal dysfunction indicates an increased 
amino acid oxidation. Amino acid supplementation did not result in the improvement of any 
tertiary functional outcome measures assessed after 90 days. In summary, further work is 
required to elucidate the intermediate-long term effects of protein or amino acid 
supplementation on skeletal muscle mass during critical illness. Physiological investigations 
that aim to characterize the metabolic changes in tissue protein balance can provide 
complementary information to clinical trials with patient-centered outcome measures. 
3. Is energy delivery an important determinant of whole-body protein balance? 
The primary aim of study IV was to investigate the difference in whole-body protein balance 
during full- or half-dose enteral nutrition, at a rate determined by measured energy 
expenditure. As energy delivery was manipulated by changing the feeding rate, the effects of 
increased calorie provision cannot be assessed separately from protein. Due to the prevalence 
of enteral formulas with a high protein/kcal ratio in our unit this also resulted in a large 
absolute mean difference in protein delivery (0.88 g/kg/day). This stands in contrast to a 
similar study protocol by Berg and co-workers using TPN in neurosurgical ICU patients, 
where mean protein delivery at full dose nutrition was 1.07 g/kg/day. Despite a large absolute 
difference in protein delivery, the observed mean difference in protein balance (7.3 
µmol/kg/h) was comparable to that in study IV (9.0 µmol/kg/h). A possible explanation is 
that the response to increasing protein delivery is non-linear and proportionally greater at 
lower intakes.  
Older studies in patients with trauma and sepsis have demonstrated a lower rate of protein 
catabolism during glucose infusions, but only in comparisons with a fasting basal state 72, 202. 
It is possible that a calorie deficit corresponding to 50% of measured EE is of lesser 
importance for net protein catabolism given an adequate provision of protein substrate. In the 
largest multicenter trial to date of enteral calorie delivery, the TARGET investigators 
randomized ICU patients to 100% or 70% of estimated calorie requirements by enteral 
nutrition. Protein delivery was similar in both groups (1.1 g/kg/day). A six-month follow-up 
using patient self-assessment did not reveal any difference in mobility or performance of 
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usual activities 116. Similar future trials investigating different levels of protein delivery 
independent of energy intake are highly warranted, and ideally be complemented by tracer 
studies or assessments of change in lean body mass.   
An important aspect to consider regarding energy provision is the duration of critical illness 
and individual metabolic rate. For patients with a prolonged ICU stay over several weeks or 
months, it is more likely that an accumulated energy deficit will have negative consequences 
in terms of body composition and functional disability at discharge. In study IV, two patients 
had a length of stay ≥4 weeks and a measured REE of ≥40 kcal/kg/day. These subjects also 
displayed the greatest increase in protein balance during full-dose EN. While it is impossible 
to draw any general conclusions from two cases, it is a reasonable assumption that similar 
outliers may benefit from different nutritional regimes than the average ICU patient. As these 
patients are underrepresented in clinical trials, there is limited evidence to guide therapy. 
Tracer investigations in conjunction with indirect calorimetry have potential to identify and 
describe specific metabolic alterations in subgroups of critically ill patients, but also to 
evaluate the response to treatments. This is an area of great interest for future research in ICU 
metabolism. 
4. Limitations of studies III and IV 
Both studies in this section have several limitations in common. The main issues are the small 
sample sizes and heterogeneity of patients enrolled, which limits the external validity and 
potential for inference from our findings to a general ICU population. The reasons for this are 
primarily related to the methodology used: 
i) Both protocols required a long period (28-48 hours) of relatively stable conditions and 
access to the patient by research staff. Protocol violations due to external clinical 
circumstances were therefore frequent, leading to a high dropout rate. This was 
particularly challenging in study IV. Further enrollment towards the recruitment target 
was halted due to a restructuring of the local pharmaceutical organization, resulting in 
a shortage of stable isotope tracers.   
ii) There is a high cost of performing tracer studies, both in terms of materials, clinical 
research staff, laboratory facilities and personnel.  
iii) The broad inclusion criteria with regard to age, anthropometric characteristics, acute 
disease states, comorbidities and duration of ICU stay increase heterogeneity of the 
patient sample. Despite this, most patients screened were not eligible to participate. 
Further limiting the scope of studies by narrowing inclusion criteria would likely have 
made recruitment even more difficult. 
Other limitations of our method, such as the uncertain clinical importance of changes in 
whole-body protein balance, potential adaptations to changes in macronutrient intake over 
time and the general caveats of the stable isotope tracer dilution technique, have been 
discussed previously.  
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There was an imbalance in the ratio of male/female patients in studies III and IV. In study IV, 
protocol violations were more common in female patients. We could not determine any other 
reasons for this skewed sampling, beyond the fact that a higher proportion of men (~60%) 
were admitted to our ICU during the study periods 205. For future investigations it is 
important to consider balancing recruitment with regard to sex, as this factor may influence 
metabolic alterations during critical illness. 
Increasing macronutrient delivery has potentially harmful effects that were not considered in 
our studies. Other research groups have hypothesized that exogenous amino acids may be 
detrimental to ICU patients, mediated by the inhibition of autophagy 153, 164. We did not 
attempt to measure the simultaneous effects of the interventions in studies III and IV on 
protein kinetics and autophagy regulation. Ideally this will be addressed in future studies. 
5. Strengths of studies III and IV 
The main strength of studies III and IV lies in the novel application of the stable isotope 
tracer method in this population. Our research group is the first to use a combination of 
enteral and intravenous tracers to quantify the contribution of enteral exogenous tracee in 
critically ill patients. Previous studies have been limited to assessing patients in a fasted state 
or during TPN, but early enteral feeding has since become standard care in ICU nutrition. Our 
method enables the quantification of whole-body protein balance, synthesis and breakdown in 
a modern ICU setting without restrictions in inclusion criteria that would limit external 
validity. 
The studies in this thesis are also among the first to investigate the effect of nutritional 
interventions on whole-body protein balance, under circumstances resembling current clinical 
practice in intensive care. Earlier work has generally been limited to the transition from basal 
to fed state using glucose infusions or intravenous hyperalimentation with TPN 61, 72, 202, 206. 
Prior studies by our own research group investigating enterally fed ICU patients have focused 
on short-term changes in protein kinetics from nutritional interventions 149, 150. Despite the 
technical challenges of a longer protocol, studies III and IV demonstrate that it is possible to 
monitor the effect of macronutrient therapies on protein kinetics in enterally fed ICU patients 
over the course of 24-48 hours. 
In study III we excluded patients with CRRT due to the uncertain loss of tracee over the 
hemodialysis membrane. In study IV we addressed this limitation by measuring and adjusting 
for the rate of phenylalanine accumulation in the effluent. As patients with acute kidney 
injury (AKI) represent a population subset with higher illness severity and increased risk of 
adverse outcomes, they are of particular interest when attempting to characterize metabolic 
alterations in critical illness. The successful inclusion of patients with dialysis-dependent AKI 
represents an advance in the execution of tracer studies in an ICU setting, and this method 
should be applied in future works.  
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7 CONCLUSIONS 
The main conclusions of this thesis are summarized below:  
• The agreement between Deltatrac and instruments using breath-by-breath technology 
in mechanically ventilated patients is variable. With the exception of one device, next 
generation indirect calorimeters have performance characteristics more closely 
aligned to the previous standard in monitoring than what is generally accepted in 
other fields (studies I and II). 
• The supplementation of an amino acid infusion to standard nutritional therapy 
improved whole-body protein balance in critically ill patients for up to 24 hours. 
(study III). 
• Providing full-dose compared to half-dose enteral nutrition in relation to energy 
expenditure improved whole-body protein balance in critically ill patients with 
established enteral feeding. The relative contributions of energy or protein intake to 
this result cannot be discerned (study IV). 
• An increased provision of parenteral or enteral amino acids did not result in increased 
amino acid oxidation during the study periods (studies III and IV). 
• Although not a pre-defined aim, we demonstrate that a stable isotope tracer protocol 
can be used in heterogenous samples of ICU patients to monitor changes in whole-
body protein kinetics from nutritional interventions (study III and IV).   
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8 FUTURE PERSPECTIVES 
The methods evaluated in this thesis provide information about individual physiology that is 
normally unavailable to the clinician. To be of value for the patient, this information must 
both be accurate and applicable in clinical decision-making.  
Regarding the measurement of energy expenditure, we view the performance characteristics 
of commercially available indirect calorimeters as acceptable for bedside and research 
applications. The alternative, using anthropometric formulas in estimating energy targets, has 
been demonstrated to be highly inaccurate in multiple studies. An exploratory analysis of our 
own results supports these previous observations. 
However, the consequences of over- or underfeeding for patient-centered outcomes are 
uncertain and not addressed in this thesis. Results from study IV indicate that matching intake 
to measured energy expenditure may improve whole-body protein balance. Due to the limited 
sample size and confounding factor of protein delivery, this conclusion should strictly be 
viewed as hypothesis-generating. Despite observed correlations between macronutrient 
deficits and mortality during critical illness, major RCTs have not found a clear signal 
indicating benefit or harm from increasing calorie provision in a general ICU population.  
A measured interpretation of these results should acknowledge both the strengths and 
limitations of large-scale clinical trials with broad inclusion criteria and standardized 
interventions. Although the average effect of higher or lower energy targets can be estimated 
with a relatively high degree of certainty from available evidence, this may be insufficient to 
inform clinical practice in all cases. It is hypothetically plausible that patients with persisting 
hypermetabolism, poor baseline nutritional status and a prolonged ICU course are at 
increased risk of harm from an accumulated negative energy balance. Another aspect to 
consider is the consequence of energy deficits after ICU discharge. In clinical trials of ICU 
nutrition, patients typically receive the intervention for the duration of ICU stay. The time 
spent in regular hospital wards generally exceeds that in intensive care, and return to adequate 
oral intake after liberation from mechanical ventilation is often delayed 35. Indirect 
calorimetry may have a role in optimizing nutritional support for patients with a long 
hospitalization and rehabilitation period after critical illness. These questions remain to be 
addressed in clinical trials.  
For future research, indirect calorimetry is an important tool to further characterize the 
metabolic alterations during critical illness. As an example, the contribution of endogenous 
substrates to energy expenditure over time is still unknown but central to the conceptual 
model of a bi- or multiphasic stress response. Multiple tracer protocols using labeled glucose, 
glycerol or palmitate in combination with indirect calorimetry could potentially shed light on 
this matter. Longitudinal trends in energy expenditure during prolonged critical illness and 
recovery also remain to be described.   
The tracer protocols used in this thesis also have promising future applications. Studies III 
and IV indicate that an increase in exogenous amino acids improves whole-body protein 
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balance in ICU patients. Although the small sample sizes warrant a cautious interpretation, 
this general trend is in accord with findings of previous kinetic investigations. 
Heterogeneity, however, makes inference more problematic. Both studies have large 
between-patient variations in body mass, length of stay, admission diagnosis and metabolic 
rate. Future tracer research in intensive care should attempt to precisely define the study 
population of interest, narrowing inclusion criteria based on one or more of the characteristics 
listed above. Biomarkers or metabolomic profiles may potentially be of value to this end 207. 
Combining tracer protocols with longitudinal assessments of body composition or muscle 
biopsies could also provide information relevant to the development of metabolic phenotypes 
as conceptual models, which can then be used to inform the design of adequately powered 
clinical trials. The main impediment to these types of in-depth physiological characterizations 
is the complexity in study design, limiting the number of patients eligible for inclusion and 
reducing sample sizes due to high costs. This may lower external validity and risks yielding 
granular information only applicable to individual patients. Cooperation between research 
groups and a common international research agenda on ICU metabolism is probably 
necessary to move beyond these issues and towards a potential future of precision medicine. 
Another question raised by studies III and IV is the effect of nutritional interventions on 
regional protein balance, particularly in skeletal muscle. This could be answered by 
combining whole-body protein kinetics with a lower limb arteriovenous balance technique 
during different levels of protein substrate delivery. The potential for combined or synergistic 
effects on skeletal muscle protein balance using amino acid supplementation and exercise is 
also an intriguing area of research. Currently there is at least one clinical trial investigating 
the effects of combined in-bed cycling and parenteral amino acids on functional disability and 
muscle cross-sectional area in ICU patients 208. Stable isotope tracers in combination with 
biopsies could provide additional information regarding the physiological effects of these 
interventions on skeletal muscle, and aid in the interpretation of observed patient-centered 
outcomes. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Människans fysiologi är en konsekvens av miljontals år av evolution. Mekanismer för hur vi 
hanterar påfrestningar från omgivningen är centrala för vår överlevnad, och är därför starkt 
bevarade över artgränserna. Ett sådant fenomen är de omfattande förändringar i 
ämnesomsättning som inträffar vid svår akut sjukdom. För att hantera vävnadsskada, 
infektion eller syrebrist på ett ändamålsenligt sätt behöver kroppen öka aktiviteten i flera 
organ, framför allt immunförsvaret. Denna omställning är en energikrävande process. 
Kroppen tillhandahåller energi och aminosyror för proteinsyntes genom att bryta ner 
befintliga reserver av fettväv och protein, ibland med en uttalad förlust av skelettmuskulatur 
som konsekvens.  
För patienter som behöver intensivvård på grund av svikt i vitala funktioner är detta katabola 
tillstånd ett stort problem. Det är väl dokumenterat att patienter snabbt förlorar muskelmassa 
under intensivvården. Detta riskerar att bidra till svaghet och funktionsnedsättning, som kan 
vara bestående under flera års tid. Ett möjligt sätt att minska dessa skadeverkningar är genom 
särskild hänsyn till patienters näringsintag. Omfattande kliniska prövningar har hittills inte 
visat någon effekt på överlevnad eller funktionsnivå genom högre eller lägre energitillförsel 
under intensivvårdsförloppet. Generellt rekommenderas en hög proteintillförsel vid kritisk 
sjukdom, men det vetenskapliga underlaget för sådana rekommendationer är svagt.  
En brist i nutritionsforskning inom intensivvård är att allmänna åtgärder ofta utvärderas utan 
hänsyn till individens fysiologi. Energibehovet hos svårt sjuka patienter är mycket varierande, 
men kan uppskattas genom att mäta syrekonsumtion och koldioxidproduktion, så kallad 
indirekt kalorimetri. Dessa mätningar sker sällan rutinmässigt inom intensivvården. Ett hinder 
är att kommersiellt tillgänglig utrustning är otillräckligt utvärderad i denna patientgrupp. Det 
är också ofullständigt kartlagt om energitillförseln i relation till uppmätt förbränning har en 
proteinsparande effekt, samt hur intensivvårdspatienter hanterar extra tillförsel av protein 
eller aminosyror på helkroppsnivå. Detta avhandlingsarbete syftar till att förbättra 
kunskapsläget i metoder för att utvärdera ämnesomsättning vid kritisk sjukdom. Det avser 
också att stärka vår insyn i de fysiologiska effekterna av energi- och proteintillförsel vid 
intensivvård.  
Huvudfrågeställningen för studie I och II var hur väl det mest beprövade instrumentet för 
indirekt kalorimetri, Deltatrac (Datex-Ohmeda, Helsingfors, Finland), överensstämde med 
andra mer moderna instrument vid jämförelser i ventilatorbehandlade intensivvårdspatienter.  
I studie I jämfördes Deltatrac med Quark RMR (Cosmed, Rom, Italien) och CCM Express 
(Medgraphics Corp, St Paul, Minneapolis, USA). Intensivvårdspatienter med invasiv 
respiratorbehandling och syrgasfraktion ≤0.5 rekryterades till studien. Mätningar av vilande 
energiförbrukning utfördes i följd med samtliga instrument i slumpmässig ordning. Det 
genomsnittliga värdet för uppmätt energiförbrukning skiljde sig inte mellan Deltatrac och 
Quark RMR. CCM Express mätte i genomsnitt cirka 60% högre värden än de andra 
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instrumenten. Orsaken till skillnaderna mellan instrumenten kunde inte utrönas inom ramen 
för den aktuella studien.  
I studie II jämfördes gasutbytesmätningar mellan Deltatrac och ett nytt instrument för indirekt 
kalorimetri, E-sCOVX (GE Healthcare, Helsinki, Finland). Då vi använde en uppdaterad 
metodologi utfördes dessutom en ny jämförelse mellan Quark RMR och Deltatrac. Till 
skillnad från studie I genomfördes mätningarna med referensmetoden och de nyare 
instrumenten samtidigt. Större hänsyn togs till att utesluta felkällor och data samlades in 
elektroniskt för granskning och bearbetning. Resultaten visade att överenstämmelsen med 
Deltatrac var i stort sett likvärdig för Quark RMR och E-sCOVX. Spridningsmåttet vid 
jämförelserna var lägre än för andra vedertagna mätmetoder inom intensivvård. Vi kunde inte 
bestämma varför skillnaderna mellan instrumenten var större vid vissa mätningar, men 
tillverkarnas eftergranskning av datan gav upphov till hypoteser som bör beaktas vid 
utveckling av ny teknik.  
Studie III och IV tillämpade en så kallad tracer-metod för att undersöka effekten av 
näringstillförsel på förändringar i proteinomsättning hos intensivvårdspatienter. Isotopmärkta 
aminosyror (”tracers”), med annorlunda molekylär vikt men i övrigt samma struktur och 
funktion som de mest vanligt förekommande naturliga motsvarigheterna, gavs intravenöst 
och via en sond i magsäcken under studiernas gång. Genom upprepad provtagning och 
analyser av kvoten mellan tracers och vanliga aminosyror i blodbanan kan hastigheten för 
nedbrytning och syntes av kroppseget protein uppskattas. Utifrån dessa storheter kan netto-
balansen beräknas, det vill säga om patienten till större del bygger upp eller bryter ner 
funktionella proteiner. 
Studie III undersökte huruvida vuxna intensivvårdspatienter kan tillgodogöra sig extra 
aminosyror under en längre tids observation. Efter en baslinjemätning av proteinkinetik gavs 
en kommersiellt tillgänglig intravenös aminosyrablandning (Glavamin) i 24 timmar. 
Proteinbalansen bestämdes på nytt efter tre timmars infusionstid samt ett dygn senare. 
Resultaten visade att patienterna i genomsnitt förbättrade sin proteinbalans, från negativ till 
positiv, och att förändringen var bestående under hela infusionstiden. Estimerad förbränning 
av aminosyror ökade inte heller under studietiden. Studien kompletterar en tidigare 
undersökning av vår forskargrupp som visade en positiv effekt på helkropps proteinbalans 
med samma intervention i upp till tre timmar.             
I studie IV ville vi undersöka om full (>80% av uppmätt energiförbrukning) energitillförsel 
via sondmat resulterade i en bättre proteinbalans jämfört med om halva dosen 
administrerades. Patienter med respiratorbehandling och etablerad sondnäring fick ingå i 
studien. Proteinkinetik bestämdes efter 24 timmar med full dos respektive halv dos av 
sondmat. Ordningen avgjordes via randomisering och patienterna fick tjäna som sina egna 
kontroller i en s.k. cross over-design. Vid full dos nutrition var både kalori- och 
proteintillförseln betydligt högre än vid halv dos. Helkropps proteinbalans förbättrades också, 
från i genomsnitt netto negativ till positiv. Till skillnad från studie III hade protokollet 
modifierats för att omfatta patienter med kontinuerlig hemodialys, vilket aldrig tidigare 
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genomförts i tracer-studier. Den beskrivna metoden är relevant för framtida användning då 
patienter med akut njurskada utgör en särskilt sårbar grupp av intensivvårdsfall. 
Sammanfattningsvis kunde vi visa att flera av den nya generationens instrument för indirekt 
kalorimetri ger resultat jämförbara med den metod som ofta anses vara mest tillförlitlig i en 
intensivvårdskontext. Resultaten från tracer-studierna antyder också att intensivvårdspatienter 
kan tillgodogöra sig tillförd näring för att minska nettoförlusten av kroppseget protein. Både 
tillförseln av intravenösa och enterala aminosyror, samt kaloriinnehåll i näringen, kan vara av 
betydelse i detta avseende. Metoderna som använts visar också på möjligheten att undersöka 
effekten av näringsterapi på proteinkinetik under ett brett spektrum av kliniska 
omständigheter i en modern intensivvårdsmiljö. Både indirekt kalorimetri och tracerstudier är 
centrala redskap i framtida arbeten som syftar till en djupare förståelse av metabolism- och 
näringsfysiologi vid kritisk sjukdom. 
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12 ERRATA TO PUBLISHED PAPERS 
 
Study I 
P. 119, section 2.1, first paragraph: 
“…extracorporeal machine oxygenation…” should read ”…extracorporeal membrane 
oxygenation…”. 
P. 119, section 2.3.1, first paragraph: 
“The air exhaled by the patient…” should read “The gas exhaled by the patient…” 
P. 120, section 3.1, first paragraph: 
“Repeated readings of REE from the same instrument gave a coefficient of variation for…” should 
read “Repeated readings of REE from the same instrument gave a percentage difference between the 
first and second measurement (mean ±SD) for…” 
P. 120, Fig. 2: 
The solid black dots in both Bland-Altman plots are displaced duplicate values. The circled white dots 
indicate the correct values.  
Study II 
P. 6 of 9, Discussion, fifth paragraph: 
“…a precision (coefficient of variation (CV)) of 20 %.” should read “…a precision (=2*coefficient of 
variation (CV)) of ±20 %.” All following references in the text to “precision” should refer to this 
definition (2*CV).  
P. 7 of 9, Discussion, sixth paragraph: 
“This was based on observational data derived from a study of supplemental parenteral nutrition…” 
should read “This was based on an observation derived from a study of supplemental parenteral 
nutrition… 
Study III 
P. 3 of 8, Statistics: 
“… a recruitment target of n = 10 was determined sufficient to assess the primary endpoint with 80% 
power…” should read “…a recruitment target of n = 10 was determined sufficient to detect a change 
in the primary outcome from negative to net zero with 80% power…” 
P. 5 of 8, Table 2, column “Completed protocol (n = 8)”: 
Row “AA intake baseline (g/kg/24 h)”: 1.11 (0.59-1.72) should read 1.11 (0.71-1.72). Row “AA 
intake with IV amino acids (g/kg/24 h)”: 2.07 (1.56-2.68) should read 2.07 (1.68-2.68). 
